EP2802417B1 - Mikrofluidisches reaktorsystem - Google Patents

Mikrofluidisches reaktorsystem Download PDF

Info

Publication number
EP2802417B1
EP2802417B1 EP13703175.3A EP13703175A EP2802417B1 EP 2802417 B1 EP2802417 B1 EP 2802417B1 EP 13703175 A EP13703175 A EP 13703175A EP 2802417 B1 EP2802417 B1 EP 2802417B1
Authority
EP
European Patent Office
Prior art keywords
bellows
reaction chamber
pump
fluid
chamber
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP13703175.3A
Other languages
English (en)
French (fr)
Other versions
EP2802417A2 (de
Inventor
Frederick C. Battrell
John Clemmens
Isaac Sprague
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revvity Health Sciences Inc
Original Assignee
Micronics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/346,615 external-priority patent/US9056291B2/en
Application filed by Micronics Inc filed Critical Micronics Inc
Publication of EP2802417A2 publication Critical patent/EP2802417A2/de
Application granted granted Critical
Publication of EP2802417B1 publication Critical patent/EP2802417B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/50273—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the means or forces applied to move the fluids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F31/00—Mixers with shaking, oscillating, or vibrating mechanisms
    • B01F31/65—Mixers with shaking, oscillating, or vibrating mechanisms the materials to be mixed being directly submitted to a pulsating movement, e.g. by means of an oscillating piston or air column
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/04—Exchange or ejection of cartridges, containers or reservoirs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06—Fluid handling related problems
    • B01L2200/0684—Venting, avoiding backpressure, avoid gas bubbles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/06—Fluid handling related problems
    • B01L2200/0689—Sealing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/14—Process control and prevention of errors
    • B01L2200/141—Preventing contamination, tampering
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/16—Reagents, handling or storing thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/02—Identification, exchange or storage of information
    • B01L2300/021—Identification, e.g. bar codes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/04—Closures and closing means
    • B01L2300/041—Connecting closures to device or container
    • B01L2300/043—Hinged closures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0609—Holders integrated in container to position an object
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0627—Sensor or part of a sensor is integrated
    • B01L2300/0636—Integrated biosensor, microarrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0822—Slides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
    • B01L2300/0867—Multiple inlets and one sample wells, e.g. mixing, dilution
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
    • B01L2300/0877—Flow chambers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0887—Laminated structure
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/12—Specific details about materials
    • B01L2300/123—Flexible; Elastomeric
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/14—Means for pressure control
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/043—Moving fluids with specific forces or mechanical means specific forces magnetic forces
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
    • B01L2400/0433—Moving fluids with specific forces or mechanical means specific forces vibrational forces
    • B01L2400/0439—Moving fluids with specific forces or mechanical means specific forces vibrational forces ultrasonic vibrations, vibrating piezo elements
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
    • B01L2400/0487—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
    • B01L2400/0487—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics
    • B01L2400/049—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics vacuum

Definitions

  • the present invention relates the general field of biological assays, and more particularly to a microfluidic apparatus for conducting cellular, enzymatic, chemical and molecular biological processes on a solid substrate, generally a glass slide.
  • Detection of biomarkers at the point of care has the potential to offer real time diagnostic information, improve patient care outcomes, decrease sample volumes, and provide analytical information from a broad range of biological samples, many of which may be acquired relatively non-invasively.
  • a device for providing a hybridization chamber is described in US 2006/0003440 A1 .
  • a device having a main body the main body is provided on a base plate. Between the base plate and the body a seal is provided such that in the recess which is surrounded by the seal a chamber is provided.
  • microfluidic device-based assays enable small-volume sampling, with point-of-care results from a broad variety of biological fluids and samples in real time, and optionally, assay cartridges that work with single use reagent packs, or are fully self-contained and operable entirely by hand.
  • ELISA® enzyme-linked immunosorbent assay
  • Bioassays adapted to a robust microfluidics device format include solid phase affinity-capture assays such as those based on antibody/antigen, antigen/antibody, antibody/protein A, glycomer/lectin, and, generally, signal molecule/receptor as targe affmity-capture pairs.
  • solid phase affinity-capture assay systems for ELISA include antibody/antigen, antigen/antibody, antibody/protein A, streptavidin/avidin, and histidine/NTA targe affinity-capture pairs.
  • Enzyme-linked antibodies, antigens, streptavidin, and histidine-rich proteins are generally available or may be synthesized by techniques well known in the art.
  • Detection systems for immunoaffinity capture and tagging or amplification of target biomarker signals include, for example, enzyme-linked conjugates and chromogenic substrates (immunochromogenic and ELISA-type detection), streptavidin-enzyme conjugates (again with ELISA-type or immunochromogenic detection), antibody-coupled beads, antigen-coupled beads (with immunoprecipitin or agglutination-type detection), protein A-coupled beads, streptavidin-coupled beads, and enzyme- or bead-conjugated protein-histidine -nickel chelates.
  • Beads for tagging can be colored, fluorescent, luminescent, tagged with radio- frequency transmitters, or otherwise labeled so that binding or agglutination can be readily detected. Titrations and binding neutralization assays also provide detectable endpoints.
  • the micro fluidic device-based immunoassays disclosed here also anticipate the use of magnetic beads in affinity concentration steps or mixing.
  • micro-eductive mixing By pairing bellows pumps inside the body of a microfluidic device, the system can be completely closed (without venting) during operation, a useful precaution against operator exposure to the contents of the device.
  • a device or apparatus disclosed herein is a combination of a first bellows pump fluidly connected by a first flow constricting aperture to an assay chamber and an opposing second bellows pump fluidly connected by a second flow constricting aperture to the assay chamber, wherein the bellows pumps are configured with pneumatic actuators for tandem operation whereby fluid is pumped back and forth through the assay chamber without venting, and further wherein the first and second flow constricting apertures are configured for micro-eductive mixing, the assay chamber further comprising an affinity capture site for heterogeneous binding assay.
  • a method for heterogeneous binding assay in a microfluidic device comprising the steps of: pumping a fluidized sample containing a target analyte back and forth across an affinity capture site without venting, said pumping step further comprising micro-eductive mixing with tandem bellows pumps; and detecting bound target analyte.
  • a microfluidic card for performing heterogeneous binding assays comprising: a) a first bellows pump fluidly connected by a first flow constricting aperture to an assay chamber; and b) a second bellows pump fluidly connected by a second flow constricting aperture to said assay chamber, wherein: i) said first and second bellows pumps comprise pneumatic actuators for tandem operation whereby fluid is pumped back and forth through said assay chamber without venting; ii) said first and second flow constricting apertures are configured for micro-eductive mixing; and iii) said assay chamber further comprises an affinity capture site for heterogeneous binding assay.
  • said card further comprises: a) a plastic card body with external surfaces encasing: i) said first bellows pump, wherein said first bellows pump comprises a first pump cavity bisected in coronal plane by a first flexible diaphragm, said first flexible diaphragm dividing said first pump cavity into an upper half-chamber and a lower half-chamber; ii) said second bellows pump, wherein said second bellows pump comprises a second pump cavity bisected in coronal plane by a second flexible diaphragm, said second flexible diaphragm dividing said second pump cavity into an upper half-chamber and a lower half-chamber; and iii) said assay chamber, wherein said assay chamber has a volume V2 and further comprises a test field with immobilized affinity agent and a transparent cover, wherein both of said lower half-chambers of said first and second bellows pumps are adapted for receiving a fluid, and wherein both of said lower half-chambers of said
  • each of said first and second flexible diaphragms are comprised of an elastomeric film sealingly affixed to said plastic card body so as to isolate fluid within said plastic card body from said external surfaces.
  • the microfluidic card further comprises sanitary means selected from the group consisting of: a) sanitary means for fluid porting; b) sanitary means for air venting; c) sanitary means for valving; and d) sanitary means for capturing waste.
  • sanitary means selected from the group consisting of: a) sanitary means for fluid porting; b) sanitary means for air venting; c) sanitary means for valving; and d) sanitary means for capturing waste.
  • said sanitary means for fluid porting comprises a sample inlet port adapted for single entry of a sample fluid without contamination of said external surfaces.
  • said sanitary means for air venting comprises a gas-permeable: water impermeable filter barrier configured to prevent escape of fluid from the microfluidic card.
  • said sanitary means for valving comprises: a) a microcavity in said plastic card body, said microcavity having an upper wall, a lower rim and a bottom plate; b) a first microfluidic channel entering said microcavity through said bottom plate at a first via; c) a second microfluidic channel entering said microcavity through said bottom plate at a second via, said first and second vias separated by a valve sill; d) a flexible film attached to said lower rim around the full circumference of said microcavity, said film having a first surface facing said bottom plate, and a second surface facing said upper wall, said flexible film configured to alternate between a first position, wherein said first surface of said film is sealingly seated against both said first and second vias and said valve sill, and a second position, wherein said second surface of said film is contacting said upper wall; and e) a microfluidic pneumatic control channel entering said microcavity through said upper wall and configured to
  • said sanitary means for capturing waste comprises: a) a waste receiving reservoir having a waste fluid channel end and a vent end; b) an absorbent bat disposed within said waste receiving reservoir and contacting said waste fluid channel end; and c) a flexible film disposed within said waste receiving reservoir and having a first side facing said absorbent bat and a second side facing said vent end, wherein said flexible film is sealed to said plastic body such that said flexible film separates said vent end and said waste fluid channel end, wherein said vent end comprises a vent exiting said external surface of said plastic body.
  • said vent further comprises a gas- permeable: water impermeable filter barrier.
  • said volume VI, diameter DI, and said aperture dimensions YI, ZI, and LI are configured for micro-eductive mixing.
  • a microfluidic card comprising an on-board waste fluid isolation apparatus
  • said on-board waste fluid isolation apparatus comprising: a) a plastic body having an external surface and encasing a waste receiving reservoir having a waste fluid channel end and a vent end; b) an absorbent bat disposed within said waste receiving reservoir and contacting said waste fluid channel end; and c) a flexible film separatingly disposed within said waste receiving reservoir and having a first side facing said absorbent bat and a second side facing said vent end, wherein said flexible film is sealed to said plastic body such that said flexible film isolatingly separates said waste fluid channel end and said vent end, wherein said vent end further comprises a vent exiting said external surface of said plastic body.
  • said vent further comprises a gas- permeable: water impermeable filter barrier.
  • kits for performing a heterogeneous binding assay on a clinical sample comprising a microfluidic card of the foregoing arrangements.
  • kits for performing a heterogeneous binding assay on a clinical sample comprising a microfluidic card of the foregoing arrangements.
  • a method for performing heterogeneous binding assays in a microfluidic device comprising the steps of: a) pumping a fluidized sample comprising a target analyte back and forth across an affinity capture site between tandem bellows pumps without venting; and b) detecting target analyte bound on said affinity capture site, wherein said pumping step further comprises pumping said fluidized sample through an aperture and micro-eductively mixing said fluidized sample.
  • said step for detecting a target analyte bound on said affinity capture site comprises detecting a bound chromogenic or fluorescent tag.
  • said step for detecting a target analyte bound on said affinity capture site comprises detection by direct or indirect ELISA.
  • a microfluidic card for performing agglutination assays comprising a serpentine channel, an affinity capture agent comprising a bead or cell, and an optical window for detecting an agglutination reaction upstream from an on-board waste fluid isolation apparatus.
  • said on-board waste fluid isolation apparatus comprises: a) a plastic body having an external surface and encasing a waste receiving reservoir having a waste fluid channel end and a vent end; b) an absorbent bat disposed within said waste receiving reservoir and contacting said waste fluid channel end; and c) a flexible film separatingly disposed within said waste receiving reservoir and having a first side facing said absorbent bat and a second side facing said vent end, wherein said flexible film is sealed to said plastic body such that said flexible film isolatingly separates said said waste fluid channel end and said vent end, wherein said vent end further comprises a vent exiting said external surface of said plastic body.
  • said vent further comprises a gas-permeable:water impermeable filter barrier.
  • an apparatus for sealingly enclosing a first aspect of a substrate member in a reaction chamber and reacting organic matter bound thereon comprising: a) a baseplate member having a first surface, wherein the first surface comprises a platform medially disposed thereon, the platform having a top surface dimensioned for contactingly receiving the first aspect of the substrate member in juxtaposition with the top surface thereof, and outside edges and outside lateral wall surfaces therearound, wherein the top surface is interrupted by a recess defined by interior walls having a height ranging from 5 to 100 micrometers, a recessed slab connecting the bottom edges of the interior walls, and a flat boundary ledge connecting the top edges of the interior walls and the outside edges of the platform, the flat ledge for supporting the first aspect of the substrate member thereon, whereby a reaction chamber with headspace volume is formed between the recessed slab and the first aspect of the substrate member when sealed to the flat ledge; b) a gasket member fitted to
  • the first aspect of a substrate member is generally a planar face of a plate-like solid, such as a glass slide or a silicon chip.
  • the planar face of the substrate can form a lid over the reaction chamber; in another view the reaction chamber can form a lid over the planar face, and the reaction chamber is thus a shallow tray enclosing a volume between two juxtaposed surfaces.
  • the reaction chamber encloses organic matter bound to the face of the planar substrate exposed to the sealed chamber so that it is wetted by liquid reagents passed through its volume, which is variable in length and width, but is of a generally microfluidic dimension in depth.
  • a first bellows pump will be fluidically connected to a first volume of said headspace volume and said second bellows pump will be fluidically connected to a second volume of said headspace volume.
  • the bellows pumps thus form a pair; multiple pairs of bellows pumps may be used.
  • the bellows pumps may be pneumatically driven. Pneumatic actuation may include a positive stroke and a negative suction stroke.
  • a reciprocating flow across the face of the substrate member is driven by repetitively actuating the first and second bellows pumps by applying a positive pressure pulses to each said bellows pumps in alternation.
  • reciprocating flow may also be driven by applying a positive pressure pulse to the first bellows pump and a suction pressure pulse to the second bellows pump, and then reversing the polarity of the pressure pulses applied to each bellows pump.
  • the bellows pumps may be magnetically driven, as when powered by electromagnets.
  • the apparatus comprises a plurality of pairs of bellows pumps, each bellows pump of said pair having a fluidic connection to the reaction chamber, wherein the pairs of bellows pumps are disposed to drive fluid flow back and forth across and through the reaction chamber.
  • the reaction chamber may be provided with an observation window is formed in the gasket or in the baseplate, or both, thus allowing for epifluorescent and/or transmission microscopy, for example.
  • the bellows pumps may be disposed proximate to the platform, such as laterally thereto or on top of or under the platform relative to the baseplate.
  • the platform is generally raised above the baseplate to facilitate sealing of the reaction chamber with a gasket.
  • the gasket member comprises a web member for coveringly and sealingly enclosing a first aspect or segment of the substrate member or glass slide on top of the boundary ledge and a peripheral skirt member for sealingly engaging the outside edges and outside lateral wall surfaces of the platform.
  • the gasket is preferably molded of an elastomer such as a silicone or a vinyl rubber and the observation window is generally formed in the web.
  • a cutout is formed on a lateral aspect of the gasket for sealedly enclosing the first aspect of the substrate member in the reaction chamber and a projecting segment of the substrate member outside the reaction chamber, thereby exposing projecting segment outside the sealed reaction chamber.
  • the cutout is adapted for receiving a glass slide having an electrode array junction and wire harness mounted on the exposed second segment of the glass slide.
  • an apparatus for enclosing a face or aspect of a substrate member in a sealed reaction chamber and reacting organic matter bound thereon, which comprises: a) a slide minicassette having a housing body with internal tray, gasketed peripheral rails, and end-mounted clamping members for sealingly receiving a mated substrate member and thereby forming a sealed reaction chamber, further wherein the tray is provided with a first fluidic connection adaptor and a second fluidic connection adaptor, the adaptors for establishing a fluidic channel between said sealed reaction chamber and a fluidic circuit in a baseplate module having a docking bay into which said slide minicassette reversibly inserts; b) the baseplate module having a first surface, wherein the docking bay is medially disposed thereon, the docking bay having a recessed surface dimensioned for receiving the slide minicassette, wherein the docking bay is provided with a first fluidic connection channel with sealing member and a second fluidic connection channel with sealing member, the first
  • the slide minicassette may be configured to be exchangeably dockable to a plurality of identical baseplate modules.
  • reagent reservoir or plurality of reservoirs are interchangeable, having an adaptor for removably engaging the baseplate and fluidic circuitry therein.
  • the reagent reservoirs conveniently may be packaged in kits, each reagent reservoir having a sealed fluid therein.
  • the adaptor for detachably attaching a reagent reservoir is a threaded nipple that sealingly engages a female receptacle in the baseplate, the female receptacle with fluidic connection to the fluidic circuitry in the baseplate. Fluid is withdrawn from the fluid reservoirs by the pumping action of the bellows pumps.
  • the first aspect of a substrate member is generally a planar face of a plate-like solid, such as a glass slide or a silicon chip.
  • the planar face of the substrate can form a lid over the housing body; in another view the housing body can form a lid over the planar face of the substrate, and the reaction chamber is thus a shallow tray enclosing a volume between two juxtaposed surfaces.
  • the minicassette encloses organic matter bound to the face of the planar substrate exposed to the sealed chamber so that it is wetted by liquid reagents passed through its volume, which is variable in length and width, but is of a generally microfluidic dimension in depth.
  • a first bellows pump will be fluidically connected to a first volume of said headspace volume and said second bellows pump will be fluidically connected to a second volume of said headspace volume.
  • the bellows pumps thus form a pair; multiple pairs of bellows pumps may be used.
  • the bellows pumps may be pneumatically driven. Pneumatic actuation may include a positive stroke and a negative suction stroke.
  • a reciprocating flow across the face of the substrate member is driven by repetitively actuating the first and second bellows pumps by applying a positive pressure pulses to each said bellows pumps in alternation.
  • reciprocating flow may also be driven by applying a positive pressure pulse to the first bellows pump and a suction pressure pulse to the second bellows pump, and then reversing the polarity of the pressure pulses applied to each bellows pump.
  • the bellows pumps may be magnetically driven, as when powered by electromagnets.
  • the reaction chamber may be provided with an observation window is formed in the gasket or in the baseplate, or both, thus allowing for epifluorescent and/or transmission microscopy, for example.
  • the apparatus comprises a plurality of pairs of bellows pumps, each bellows pump of said pair having a fluidic connection to the reaction chamber, wherein the pairs of bellows pumps are disposed to drive fluid flow back and forth across and through the reaction chamber.
  • the baseplate module and the slide minicassette are configured to be operated in a vertical orientation, a horizontal orientation, or an inverted orientation, and may be interfaced with an automated apparatus for performing multiple substrate member-based reactions in parallel.
  • Micro-eductive mixing refers to a unique method of mixing at a microscale, whereby the ejectate of a diaphragm-actuated pumping chamber is channeled into an adjoining channel or chamber through a "focusing" or “flow constricting” aperture, thus forming a microscale plume which entrains or "educts" the surrounding bulk fluid. While not bound by theory, mean flow velocity and hence shear rate is increased by the focusing apertures, causing exit plume microeddies characteristic of turbulent or near-turbulent flow in the receiving chamber.
  • This mixing method is referred to herein as "micro-eductive or eductive mixing”. Stagnant liquid is broken up, eliminating the need for impellers and static mixers.
  • eductive mixing or “micro-eductive mixing” is a process step whereby a liquid is forced through a microscale aperture and exits as a plume into a stagnant or slow moving bulk fluid, and the bulk fluid is entrained or educted into the rapidly moving plume, the plume further shedding eddies which mix with the educted fluid.
  • the process step bears a relationship to the "Penberthy in-tank mixer” in function, but is adapted here structurally to a microscale or microfluidic device scale and format.
  • Biomarker means a molecule or molecules associated with a physiological condition of health or pathology in a vertebrate. Biomarkers may include not only the proteome, genome and metabolome of the vertebrate host, but also the proteome, genome and metabolome of normal flora or pathogenic infectious agents of the vertebrate body, including bacterial, protozoan, and viral pathogens. Preferred biomarkers include antigens and antibodies.
  • Test samples means representative biosamples including, but not limited to, blood, serum, plasma, buffy coat, wound exudates, pus, lung and other respiratory aspirates, nasal aspirates, bronchial lavage fluids, saliva, sputum, medial and inner ear aspirates, cyst aspirates, cerebral spinal fluid, feces, urine, tears, mammary secretions, ovarian contents, ascites fluid, mucous, stomach fluid, gastrointestinal contents, urethral discharge, synovial fluid, peritoneal fluid, vaginal fluid or discharge, amniotic fluid, semen or the like.
  • Assay from swabs or lavages representative of mucosal secretions and epithelia are also anticipated, for example mucosal swabs of the throat, tonsils, gingival, nasal passages, vagina, urethra, anus, and eyes, as are homogenates, lysates and digests of tissue specimens of all sorts. Besides physiological fluids, samples of water, food products, air filtrates, and so forth may also be test specimens.
  • Solid-phase capture refers to affinity binding and concentration of an analyte or analyte: detection system complex on a solid phase particle, bead, surface, or porous adsorbent material. Solid phase capture may be achieved with immobilized antigen, antibody, avidin, nickel-NT A, lectin, or other ligand/receptor systems.
  • Target analyte or antibody Analyte is used broadly to indicate the biomarker detected by the assay, but it should be understood that antibodies may be both reagents of an assay and also analytes. By definition, the target analyte is not a reagent. For example, antibodies found in blood, mucous secretions, and tissue test samples may be diagnostic for a clinical condition. Antibodies used as detection tags are reagents. Serodiagnosis of a pathogen can occur by detection of an antibody to the pathogen. Similarly, assays may be designed to directly detect the target pathogen.
  • Capture molecule or antibody refer to reagents. Affinity capture of target analytes by capture molecules is a useful concentrating and detection means in microfluidic device-based assays.
  • Targets include analytes, ligands or antibodies.
  • Capture molecules and their respective target analyte pairs include antibody/antigen, antigen/antibody, antibody/protein A, glycomer/lectin, signal molecule/receptor, and histidine:nickel chelates. These are termed “target: affinity-capture pairs”.
  • Immunosorbent is understood in the context of an analyte-sorbent complex or antibody-sorbent complex for use in immunoassays as a solid-phase capture surface.
  • Preferred sorbent materials have relatively high surface areas and are wettable under assay conditions.
  • Sorbent materials that have been successfully "decorated” with capture agent or antibody include agarose in bead form, such as Sephadex, other carbohydrates such as dextran, cellulose and nitrocellulose, plastics such as polystyrene, polycarbonate, polypropylene and polyamide, inorganic substrates such as glass, silica gel and aluminum oxide, and high molecular weight cross-linked proteins.
  • Plastics are optionally plasma-treated to improve binding and may be masked during plasma treatment to localize binding sites in the test field.
  • Immunosorbent materials may be fabricated and used in the form of particles, beads, mats, sponges, filters, fibers, plates, and the like.
  • Immobilize Assays are built up from reagents that are soluble or are solubilized upon rehydration in the test sample, a diluent, or in another reagent, and from reagents that serve to capture and concentrate the analyte at a defined location or surface in the device.
  • the terms “immobilize” or “immobilized” as used herein indicate that test analyte and affinity capture reagent binding is in effect irreversible under conditions of the assay.
  • Agglutination refers to a class of analyte: affinity capture molecular binding interactions characterized by formation of colloidal floes or macroscopic aggregates.
  • capture molecules such antibodies are termed agglutinins.
  • Precipitins also produce agglutination- like reactions with particles.
  • Endpoint is used here as shorthand for a “result” from either qualitative or quantitative assays, and may refer to both stable endpoints where a constant activity or level is attained, and to rate reactions, where the slope of a reactant or product concentration as a function of time is monitored continuously.
  • Microfluidic device is a hydraulic device, cartridge or card with at least one internal channel, void or other structure having at least one dimension smaller than 500 microns, but in some cases twice that, as when the sample contains particles or a bead reagent is used.
  • the devices described here may be hybrids of microfluidic and microscale fluid structures, but generally require small sample volumes less than 1 mL, more preferably less than 200 ⁇ L, and most preferably less than 50 ⁇ L.
  • Microscale is taken to indicate an internal dimension less than 5 mm, but in most instances less than about 2 mm.
  • Microfluidic devices may be fabricated from various materials using techniques such as laser stenciling, embossing, stamping, injection molding, masking, etching, and three-dimensional soft lithography. Laminated microfluidic devices are further fabricated with adhesive interlayers or by thermal adhesiveless bonding techniques, such by pressure treatment of oriented polypropylene. Fabrication of injection molded micro fluidic devices may include sonic welding or UV- curing glues for assembly of parts.
  • Microfluidic channel also termed “microchannel” means a fluid channel having variable length, but cross-sectional area often less than 500 ⁇ m, in some cases twice that, as when the sample contains particles or a bead reagent is used.
  • Microfluidic fluid flow behavior in a microfluidic channel is highly non-ideal and laminar, as in Poiseuille flow, and may be more dependent on wall wetting properties and diameter than on pressure drop.
  • Hybrid microscale and microfluidic devices are encompassed here. Microfluidic channel surfaces may be passivated if desired.
  • Microfluidic valves include hydraulic, mechanic, pneumatic, magnetic, and electrostatic actuator means with at least one dimension smaller than about 500 ⁇ m, in some cases twice that, as when the sample contains particles or a bead reagent is used.
  • a representative flap valve of the genus is described in U.S. Pat. No. 6,431,212 .
  • One-way “check” valves are also known in the art and can be used to direct the flow of solubilized reagents and sample for microfluidic device-based assays.
  • Ball pinch valves as described in U.S. Pat. No. 5,718,567 , are also useful in the devices of the present invention, as may be the valves of U.S. Pat. No. 6,729,352 .
  • Microfluidic pumps are inclusive of “microscale pumps”, and include for example, bulbs, bellows, diaphragms, and bubble microactuators intended to force movement of fluids, where the structures of the pump are in fluidic connection with a microfluidic channel.
  • Such structures include the mechanically actuated recirculating pumps described in U.S. Pat. No. 6,743,399 and U.S. Patent Application Publication No. 20050106066 .
  • Such pumps may be robotically operated on operated by hand.
  • Electroosmotic pumps are also provided. Such pumps can be used in place of external drives to propulse the flow of solubilized reagents and sample in microfluidic device-based assays.
  • Bellows Pump in the pneumatic arrangement, is a device formed as a cavity, often cylindrical in shape, bisected in coronal section by an elastomeric diaphragm to form an "upper” (or first) and a “lower” (or second) half-chamber which are not fluidically connected.
  • the diaphragm is controlled by a pneumatic pulse generator generally connected to the upper half-chamber. Positive pressure above the diaphragm distends it, displacing the contents of the second half-chamber, negative gauge pressure (suction) retracts it, expanding the second half-chamber and drawing fluid in.
  • a pneumatic pulse generator is pneumatically connected to the upper half-chamber, generally by a microchannel, which is valved.
  • pneumatic actuation is programmable.
  • programmable pneumatic pressure logic used by the pulse generator will actuate the diaphragm on signal and open and close valves on signal.
  • a pneumatic manifold and solenoid valves are provided to connect the card with the controller.
  • fluid enters the lower half-chamber of a bellows pump through the inlet when negative pressure is applied to the diaphragm (or passively, when fluid is pushed in by a second bellows pump). Then, when positive pressure is applied to the diaphragm, during the downstroke, the fluid contents of the chamber are displaced out through the outlet.
  • fluid By supplying a train of positive and negative pressure pulses to a diaphragm, fluid can be moved in and out of a bellows pump chamber. This fluid motion becomes directional by the application of synchronized valve logic.
  • Pairs of bellows pumps i.e., “dual bellows pumps” can mix fluids or suspensions when configured with a first diaphragm pressure-actuated and a second diaphragm passive so as to force reciprocating flow between the two bellows chambers. Reciprocating flow can also be obtained by synchronously actuating both diaphragms with alternating or inverted pneumatic pulses. Similarly, a multiplicity of bellows pumps can be fiuidly connected in series to perform a mixing function.
  • Self-priming connotes a microfluidic channel that is fabricated from a material or is treated so that the channel is wettable and capillary flow begins generally without the need to prime the channel.
  • Via refers to a step in a microfluidic channel through a layer, most characteristic of laminated devices built from sheets or rolls, but may also be found in molded devices with multiple layers.
  • Isolation refers to a system of seals and enclosures that protect the user from exposure to clinical materials potentially contaminated with an infectious agent, toxin or unknown biohazard.
  • a single-entry device may optionally include a flexible bung which is self-sealing following withdrawal of the sample dispensing device.
  • Isolation microfluidic devices may also include vent filters and any on-board "reagent-", “waste-” or “rinse pack” sealingly enclosed within the device.
  • Medical isolation is commonly further characterized as “reverse isolation” or “forward isolation”, as would be known by those skilled in the art. Exposure may occur if the operator of the device is contacted by the sample; contamination of the sample may occur if the sample is contacted by the operator, or by a fomite, or by another sample.
  • Single entry devices are disposable, and intended for single use. Generally, one sample per device is applied, the device is then sealed, and the assay performed.
  • Swab capture devices are a means for sanitary sample capture in which the swab to be analyzed is inserted into the device and the handle is broken off so that the swab becomes sealed inside the device. Closures in which blood, plasma or other bodily fluid, or lavages, is taken up in the device by pipetting, by aspiration or by capillary action and the orifice then sealed are also recognized here as single-entry means.
  • Waste pack is a cavity or reservoir that serves as a receptacle for discharged sample, rinse solution, and waste reagents.
  • a waste pack also includes an absorbent pad, for example consisting of a fibrous bat with or without a hydrophilic polymer, and includes absorbent foams; absorbent sponges; superabsorbent polymers; or absorbent gelling materials.
  • the absorbent pad is a commonly a bibulous material and also can be used to propulse fluid flow by capillary wetting in place of, or in concert with, microfluidic pumps.
  • Other materials include papers, sponges, diaper materials, Contec-WipeTM (Contec, Spartanburg S.C. USA), for example.
  • waste packs may be used to contain biohazardous material by incorporating a flexible or elastomeric film or membrane sealingly attached to the body of the microfluidic device and enclosing the waste pack, which contains an absorbent bat, in a waste chamber inside the device body.
  • the membrane stretches as the bibulous material expands. The cavity outside the isolation layer is vented to atmosphere, but the membrane ensures that waste material is contained and isolated.
  • the bibulous material may be pre-treated to comprise a disinfectant as an added precaution.
  • Vent refers to a pore intercommunicating between an internal cavity and the atmosphere.
  • An isolation vent further is fabricated of a housing containing a membrane composition that is selected to prevent transit of fluids but is permeable to gas, thus forming a liquid barrier.
  • MuporTM a porous PTFE composition available from Porex Porous Products Group (Fairburn Ga., USA).
  • Test field refers to the site or zone in a microfluidic device-based assay where the assay endpoint is observed or measured.
  • a preferred test field is, for example, an optical window in the coverplate of the device, optionally equipped with a magnifying lens.
  • “Means for isolation” include impermeable cartridge body, gas permeable hydrophobic venting, bibulous padding in waste chamber, disinfectant in waste chamber, elastomeric membrane separating pneumatic actuator from blister pack, flexible membrane separating bibulous padding from vent, valve with elastomeric membrane actuated by suction pressure, suction pressure in said sample entry port, onboard reagent pack, single-entry sample port, and disposable device, among others.
  • Means for detecting refers to a device for assessing and displaying an endpoint, i.e., the result of an assay, and may include a detection channel and test pads. Detection endpoints are evaluated by an observer visually in a test field, or by a machine equipped with a spectrophotometer, fluorometer, luminometer, photomultiplier tube, photodiode, nephlometer, photon counter, voltmeter, ammeter, pH meter, capacitative sensor, radio-frequency transmitter, magnetoresistometer, or Hall- effect device.
  • a spectrophotometer fluorometer, luminometer, photomultiplier tube, photodiode, nephlometer, photon counter, voltmeter, ammeter, pH meter, capacitative sensor, radio-frequency transmitter, magnetoresistometer, or Hall- effect device.
  • Particles, beads and microspheres, impregnated with color or having a higher diffraction index may be used to facilitate visual or machine-enhanced detection of an assay endpoint.
  • Magnifying lenses in the cover plate, optical filters, colored fluids and labeling may be used to improve detection and interpretation of assay results.
  • Means for detection of particles, beads and microspheres may include "labels" or "tags” such as, but not limited to, dyes such as chromophores and fluorophores; FRET probes (including those known as "Molecular Beacons”), enzyme-linked antibodies and their chromogenic substrates, radio frequency tags, plasmon resonance, or magnetic moment as are known in the prior art. Colloidal particles with unique chromogenic signatures depending on their self-association are also anticipated to provide detectable endpoints.
  • QDots such as CdSe coated with ZnS, decorated on magnetic beads, or amalgamations of QDots and paramagnetic Fe 3 O 4 microparticles, optionally in a sol gel microparticulate matrix or prepared in a reverse emulsion, are a convenient method of improving the sensitivity of an assay of the present invention, thereby permitting smaller test pads and larger arrays. Fluorescence quenching assays are anticipated. A variety of substrate and product chromophores associated with enzyme-linked immunoassays are also well known in the art and provide a means for amplifying a detection signal so as to improve the sensitivity of the assay. Detection systems are optionally qualitative, quantitative or semi-quantitative.
  • Target Biomarkers Those skilled in immunology are familiar with ELISA and agglutination assays. Targets for microfluidic detection assays include diagnostic biomarkers useful in the practice of internal medicine. Classes of biomarkers suitable for ELISA are well-known in the art and include proteins and peptides associated with pathology, hormones, tissue and coagulation factors, and small molecules, etc. These would include cancer markers associated with bladder, prostate, breast or lung cancer, for example, and also blood group antigens and antibodies useful for testing crossmatch compatibility.
  • Targets also include infectious and parasitic agents.
  • laboratory diagnosis tends to rely on direct detection of the invading pathogen. This may involve in vitro culture or microscopic examination of test specimens. Test tube and microtiter plate-formatted serological methods are also useful. Non-specific assays such as cold-agglutinins or sedimention rate of whole blood are also used to support the clinical impression. Definitive laboratory tests rely extensively on live culture. But for a number of reasons, this is not fully satisfactory. Culture methods are plagued by delays, sample contamination, false negatives, and in the case of emerging diseases, by lack of reliable growth substrates and protocols for culture of viable organisms. Some well known but very fastidious pathogens are also not routinely cultured.
  • time to culture is unsatisfactory.
  • Blood cultures are typically, for example, not read for 14 to 20 hours, and a positive culture, indicated by turbidity in liquid broth, must be followed by isolation of the causative organism on solid media, identification by biochemical tests, with subsequent antibiotic susceptibility testing.
  • Cultures for tuberculosis typically are read 3-6 weeks after inoculation.
  • Viral culture which relies on cell and tissue culture, or inoculation of egg chorioallantoic membrane, takes one to fourteen days and is difficult at best. Detection of protozoan parasites generally relies on microscopic observations or serodiagnosis, tests that are not generally available outside of specialized clinical laboratories. In vitro testing and sample handling is also inherently unsafe and can contribute to iatrogenic infections.
  • the range of needed assays can be grasped from the following partial list of known pathogens, which must be differentiated from closely related microbial normal flora and environmental contaminants.
  • Airborne respiratory pathogens include, for example, Streptococcus pneumoniae, Streptococcus pyogenes, Mycoplasma pneumoniae, Klebsiella pneumoniae, Mycobacterium tuberculosis, Bordatella pertussis, Legionella pneumophila, Cory neb acterium diptheriae, Hemophilus influenza, Chlamydia pneumoniae, Varicella virus, Measles virus, Mumps virus, Respiratory Syncytial Virus, Coronavirus, Rubella virus, Influenza virus, including hemaglutinin group HI -5, Adenovirus and Pneumocystis carneii, among others, and for which serodiagnosis is feasible.
  • Food and water-borne enteric pathogens include, for example, Salmonella typhosa, Salmonella enteridis, Salmonella cholerasuis, Salmonella typhimurium, Shigella dysenteri, Campylobacter jejuni, Vibrio cholera, Helicobacter pylori, Escherichia coli (strains producing heat stable or heat labile enterotoxin, such as serotype O157:H7), Clostridium botulinum as a source of toxin, Clostridium perfringens, Listeria monocytogenes, Polio virus, and Hepatitis virus A and B, Entamoeba histolytic, Schistosoma mansoni, Clonorchis sinensis, Trichinella spiralis, for example.
  • Salmonella typhosa Salmonella enteridis
  • Salmonella cholerasuis Salmonella typhimurium
  • Shigella dysenteri Campylobacter jejuni
  • Blood-borne pathogens include, for example, Salmonella typhosa, Salmonella paratyphi, Bacillus anthracis, Brucella abortus, Brucella suis, Brucella melitensis, Yersinia (Pasteurella) pestis, Pasteurella multocida, Francisella tularensis, Spirillum minus, Burkholderia mallei, Leptospirum ictoerohaemorrhagiae, Coxiella burnetii, Rickettsia typhi, Hantavirus, Dengue fever virus, Yellow fever virus (and other viruses of the Flavivirus group), West nile virus, Japanese B encephalitis virus, St Louis encephalitis, Western equine encephalitis, Human immunodeficiency virus 1 and 2, Human T-cell leukemia virus 1 and 2, Dirofilaria immitis in dogs, Plasmodium vivax, falciparum, malaria,ova/e and berghei to
  • Sexually transmitted diseases include, for example, Syphilis (Treponema pallidum), Neisseria gonorrhoeae, Chlamydia trachomatis, Human Immunodeficiency virus, Papilloma virus, Herpes simplex and also Candida albicans, an ascomycete.
  • Wound and bite pathogens include, for example, Staphylococcus aureus, Streptococcus pyogenes serotypes responsible for necrotizing fasciitis, Pseudomonas aeruginosa, Clostridium perfringens, Clostridium tetani, Yersinia pestis, Bacillus anthracis, and Bacteroides fragilis. Infections resulting from bites by mosquitoes, ticks, fleas and other arthropods generally are classified as blood-borne infections.
  • Central nervous system and CSF pathogens include, for example, Neisseria meningitides, Streptococcus pneumoniae, Listeria monocytogenes, syphilis, Haemophilus influenza serotype B, Acinetobacter spp, Escherichia coli, Enterobacter spp, Pseudomonas aeruginosa, Staphylococcus aureus, viral encephalitis such as Japanese B encephalitis, Mumps virus, Polio virus, herpes viruses (HSV-1, HSV-2), varicella zoster virus, and Rabies virus, and so forth.
  • Representative urinary pathogens are dominated by gram negative rods, and include, for example, Proteus mirabilis, Proteus vulgaris, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and occasional Pseudomonas infections.
  • Normal flora of the respiratory tract include, for example, Streptococcal species, Corynebacteriaceae, and Neisseriaceae that must be differentiated from potential pathogens.
  • Normal flora of the gastrointestinal tract include, for example, Methanobrevibacter smithii, Bifidobacterium longum, Streptococcus faecalis, Firmicutes, including Clostridia and Faecalibacteria, Lactobacillaceae, Acinitobacteria, Proprionobacteriaceae, Bacteroidaceae, and Enterobacteriaceae, as well as unidentified archaebacterial groups and species.
  • Immunoassay-type solid phase affinity capture sites for a microfluidic device-based assays are optionally localized in a diagnostic card on the plane of a test field in the form of a pad, zone or site.
  • the capture molecule selected for the assay is adsorbed or crosslinked to the solid support matrix by methods known in the art.
  • Support substrates include filter pads, sponges, beads, membranes, plastics, and other solids.
  • the analyte may be coupled chemically or non-covalently to the solid phase and in others it may be incorporated into a material to be coated onto the solid surface.
  • Solid substrates of this type are used in the same manner as for dipstick technology, an analogous art.
  • an optical window is typically provided with a view of the test site.
  • Solid supports are sometimes composed of a porous material, with pore sizes available range from 0.1 micron to about 250 microns, and may include depth filters, where pore size varies with depth in the material. Such solid supports are generally hydrophilic to ensure wettability or are treated to be hydrophilic. Bibulous materials, i.e., those absorbing aqueous solutions by capillary action, are well known in the art.
  • Such materials include natural polymeric materials such as cellulosic materials (for example cotton, filter paper, chromatographic paper, nitrocellulose and cellulose acetate), agarose and crosslinked dextrans; but also include inorganic powders or fibers such as glass, silica gel, derivatized silica, diatomaceous earth, aluminum oxide; synthetic polymers such as polyethersulfones, polyesters, poly(vinyl chloride), vinyl chloride-propylene copolymer, vinyl chloride-vinyl acetate copolymer, polyacrylamides, polyacrylates, polyamides, nylons for example, wettable polyvinylidene fluoride (PVDF), either used as supplied or in composites with other materials; and ceramic materials or exploded metals.
  • the solid support should not interfere with the detection signal.
  • the porous material is typically attached to rigid or semi-rigid backing.
  • the porous material may be polyfunctional or be capable of being polyfunctionalized to enable covalent bonding of the capture molecule, for example with an aldehyde or with osmium tetroxide.
  • Capture molecules may also be immobilized by non-covalent forces. Drying is often used as a means of "fixing" biological molecules to a surface-active solid support.
  • Solid phase substrates may also selected from plastic surfaces.
  • Plastic surfaces such as polystyrene, polycarbonate, polypropylene, polyethylene terephthalate (PET), and polyamide have a native surface activity and will tightly adsorb biological molecules, but may optionally be activated to increase the density and tightness of adsorption of the capture molecule by gas plasma treatment, typically an etching gas such as nitrogen, oxygen or air (corona treatment) in plasma form. These gases serve to derivatize the polymer backbones of the solid support, creating ionizable and reactive amine and nitro groups or hydroxyl and carboxyl groups respectively.
  • Such activated surfaces may be derivatized with heterobifunctional linkers to aid in attachment of the capture molecule.
  • Glutaraldehyde pretreatment of the plastic surfaces has also been used. In general, any method known in the art for attaching the capture molecule to the immunosorbent that results in a usable solid phase affinity capture complex may be used.
  • Masking is commonly used to define boundaries within which the capture molecule will be fixed to the plastic surface. Masking to mark out a test site aids in visual recognition of a positive assay and also in machine-aided image analysis of automated test results. Plastic surfaces may be passivated outside the defined boundaries of the mask, or in negative masking techniques, the plastic surface will be activated, such as by low pressure gas plasma treatment, where unmasked.
  • Immunosorbent beads well known in the art include latex beads, agarose in bead form (such as Sepharose 4B - Pharmacia); dextran beads, crosslinked proteins prepared as microspheres, magnetic microspheres containing a ferrite core, and silicate microspheres containing fluorophores, quantum dots, or even radiofrequency tags, and modified on the surface to permit crosslinking.
  • latex beads agarose in bead form (such as Sepharose 4B - Pharmacia); dextran beads, crosslinked proteins prepared as microspheres, magnetic microspheres containing a ferrite core, and silicate microspheres containing fluorophores, quantum dots, or even radiofrequency tags, and modified on the surface to permit crosslinking.
  • Numerous forms of latex are prepared by emulsion techniques, and are available tagged with dyes, both fluorescent and colored, quantum dots.
  • Antigens can be coupled to bifluorescent beads such as those provided by Luminex Corporation (Austin Tex., USA) by a two-step carbodiimide process. Sedimentation of beads in micro fluidic device-based assays has been described, and the size is typically optimized for the application. Thus beads can serve not only as solid phase supports for affinity capture, but also as indicator or labeling agents.
  • a synthetic matrix suitable for ELISA was created by copolymerizing plastic monomers with peptides consisting of the epitope site of nonstructural protein 1 of flavivirus, in this case Dengue Virus. These molecularly imprinted polymers, were then deposited on a solid underlayer ( Dar-Fu Tai et al. "Artificial Receptors in Serologic Tests for the Early Diagnosis of Dengue Virus Infection” Clinical Chemistry 10: 1373 (2006 )). This solid phase affinity capture material performed very well in detecting seropositive sera supplied by the CDC.
  • Blocking agents in particular certain detergents and proteins, weaken non-specific interactive forces that contribute to high background signals in ELISA.
  • Blocking agents include bovine serum albumin, optionally methylated or succinylated, whole normal serum, such as horse serum or fetal calf serum, and other commercially available proteins such as casein, gelatin and non-fat dry milk.
  • Detergent-based blocking agents can also be used.
  • the types of detergents which are appropriate are selected from nonionic, amphoteric, cationic, or anionic forms, and the selection is based on the nature of the solid surfaces being blocked. Considerations which govern the selection of the appropriate detergent blocking agent are well understood in the art. It is preferred to use detergents in combination with protein-based blocking agents. Suitable detergents which can be used either alone or in admixture with the protein blocking agents include polyoxyethylene sorbitan alcohol detergents (i.e., the Tween® series), polyoxyethylene alcohols such as Nonidet P450 ® or polyoxyethylene ethers such as Triton X-100®.
  • FIG. 1 shows a microfluidic device for ELISA immunoassays.
  • the device is constructed by a lamination process from layers of clear plastic such as polyethylene terephthalate (PET), polystyrene, polycarbonates, polyacrylates, or polyesters in general, joined by interposed layers of adhesive. Microchannels, voids and holes are first machined from the plastic layers and adhesive before assembly, so that a microfluidic network is formed.
  • the device may be constructed by injection molding of a cover and base layer, optionally with interposed plastic layers of increasing complexity, the layers held together with adhesive or fused under pressure with heat or solvent.
  • FIG. 1 Shown in FIG. 1 is a simple card 1 for immunoassay development.
  • the card body is plastic and has coverplate 14 and baseplate (not shown).
  • a schematic representation of the device ports and underlying microfluidic channels, reservoirs and structures is shown.
  • Flexible layers 12 and 13 cover the fluid chambers of bellows pumps 4 and 8 and may be elastically deformed so as to propel fluid from one reservoir to the other and back in a reciprocal motion.
  • the device is backed by a rigid sheet of material (not shown) so that all internal cavities are sealed.
  • sample port 2 via microchannel 3, is used to introduce test sample into the reservoir of left bellows pump 4.
  • "waste" port 9 via microchannel 10 is used to introduce and discard reagent solutions into and out of the fluid chambers of right bellows pump 8.
  • Ports 2 and 9 extend through the device cover 14 and are continuous with the fluid chambers of bellows pumps 4 and 8.
  • Microchannels 3 and 10 may be modified to include valves (not shown).
  • Assay chamber 5 Active reciprocal flow of fluid between the right and left reservoirs is conducted through assay chamber 5 via focusing apertures 6 and 7. Note that a vent is not required for actual operation of the dual pump device because the displacement of fluid from one chamber during the pump downstroke is balanced by displacement of fluid into the other, the flexible membrane being compliant in both up and down directions.
  • Assay chamber 5 is fully sealed and contains test field 11. Test field 11 is coated with immobilized affinity capture molecule.
  • reagents Prior to assembly, reagents can be applied in or on microfluidic channels and test fields in a variety of ways.
  • Various "printing" techniques are suitable for application of liquid reagents to layers of the device, e.g., micro-syringes, pens using metered pumps, direct printing, ink-jet printing, air-brush, and contact (or filament) methods, and the layers or sheets are then assembled into the completed device.
  • sample can be injected through a self-sealing bung, or pipetted or otherwise deposited into the device and sealed with a sanitary closure such as a cap, stopper, lid or tape.
  • a pinch, ball, flap or peanut valve in the sample inlet port further seals the system. All such microfluidic cards are generally intended for single use followed by disposal.
  • test sample may be mixed first with a detection antibody, and the mixture is then passed over the capture antibody on a solid phase matrix or test zone. After free detection antibody is rinsed away, color development indicates the presence of bound analyte-detection antibody complexes.
  • U.S. Patent Application Publication No. 20060127886 teaches away from adding test sample directly to detection antibody. The ordinary person skilled in the art is familiar with ways in which the order of steps in an assay protocol may be varied.
  • the indirect ELISA is used to increase sensitivity.
  • the indirect ELISA employs a bridging ligand which is applied to bound target analyte on the solid phase capture matrix and recognizes the target analyte.
  • Bridging ligands such as antibodies to immobilized antigen, build up the immunoprecipitin lattice at the site of analyte binding.
  • detection reagent is then applied.
  • detection antibody is directed against the immunoglobin tails of the bridging antibody, not the analyte. Fivefold or more increases in the quantity of bound detection antibody can be achieved.
  • addition of color reagent results in a strong signal even in the presence of relatively low concentrations of analyte.
  • the "indirect" ELISA format has another advantage. Any number of target analytes, each forming complexes with bridging antibodies on physically separate test zones, can be detected with a common, or universal, detecting antibody.
  • an affinity capture solid phase matrix can be subdivided into smaller zones and pretreated with separate affinity capture molecules for capture and analysis of multiple analytes.
  • a test strip composed of a row of five test field zones, as bands, strips, or spots, each embodying a unique reagent, provides a plurality of affinity capture matrices for simultaneous assay of five analytes.
  • Means of applying affinity capture molecules includes the printing of bands, strips, or spots, for example with a dot-matrix printer or other dispenser (BioDot). Test fields may optionally be provided for control and validation of the assay.
  • the zones may be laid down in unique shapes, for example a "plus” sign, a "minus” sign, or a “checkmark” to indicate their significance, and are typically labeled with instructions on a cover applied to the coverplate of the device or can be read by an instrument such as an optical scanner.
  • FIG. 2 Shown in FIG. 2 is a microfluidic device 20 with coverplate 21 and baseplate (not shown) and a schematic representation of the device ports, chambers, and connecting microfluidic channels, reservoirs and structures.
  • Flexible layers 22 and 23 cover the reservoirs of bellows pumps 24 and 25 and may be elastically deformed so as to propel fluid from one reservoir to the other and back in a reciprocal motion.
  • sample port 26, via microchannel 27, is used to introduce test sample into the fluid chamber of left bellows pump 24.
  • "waste" port 28, via microchannel 29, is used to introduce and discard reagent solutions into and out of the fluid chamber of right bellows pump 25.
  • Ports 26 and 28 extend through the device cover 21 and are fluidly continuous with the fluid chamber of bellows pumps 24 and 25.
  • Microchannels 27 and 29 may be modified to introduce valves (not shown), as may be useful in sanitary applications. The mixing arrangement shown here remains operable when all external vents are closed.
  • Assay chamber 30 Active reciprocal flow of fluid between the right and left pump chambers is conducted through assay chamber 30 via focusing apertures 31 and 32.
  • Assay chamber 30 is fully sealed and contains test strip 33.
  • test strip 33 is coated with three species of immobilized affinity capture molecules in zones marked 34, 35, and 36 respectively.
  • Assay chamber volume V 2 is typically equal to, greater than, or less than pump bellows chamber volume VI.
  • An optical window typically overlies the assay chamber in these devices.
  • test strip 33 and zones 34, 35 and 36 were prepared of PET plastic and negatively masked with an adhesive protective layer.
  • the exposed plastic was then subjected to plasma etching under carbon dioxide (or argon) gas in order to derivatize the polymer backbones, which increases wetting and surface adsorption properties of the plastic.
  • carbon dioxide or argon
  • the mask is then removed and the plastic heated to 50-60° C. for a few minutes, optionally under vacuum or inert gas, to fix the molecules to the plastic.
  • the test strip is then blocked with a blocking solution to eliminate nonspecific absorption of analyte or reagents and dried before assembly into the test cavity of the microfluidic device of FIG. 2 .
  • Devices may also contain an absorbent pad or bat 38, located for example in the waste reservoir 37 of FIG. 2 .
  • Absorbent pads or bats are used to retain discarded sample and reagents, and as is well known in the art, the absorbent may also assist in promoting directional capillary action.
  • substances that may be used include cellulose, cellulose nitrate, cellulose acetate, glass fiber, nylon, polyelectrolyte ion exchange membrane, acrylic copolymer/nylon, Whatman 3M, polyethersulfone, 470 and 740-E from Schleicher and Schuell, (Keen, N.H. USA), or D28 from Whatman (Fairfield, N.J.
  • Waste receptacle 37 also includes a vent 39.
  • Said vent may be formed from a housing containing an isolation filter or membrane that prevents transit of aqueous fluids but is permeable to gas, a useful sanitary measure.
  • FIG. 3 represents a schematic of a device 40 suitable for automation or semi-automation of an ELISA assay, or other heterogeneous binding immunoassay, in a micro fluidics format.
  • right and left bellows pumps 41, 42 are used to power reciprocal fluid flow across assay chamber 43, shown here as containing two test fields (positive 44 and negative 45, see also FIG. 10 ) in which the appropriate capture molecules have been immobilized.
  • right and left valves 46, 47 controlling microfluidic channels 48, 49, 52, and 53 used in sample and reagent addition, mixing, rinsing, and in venting air during sample loading.
  • Fluid port 54 is a sample inlet port; port 55 is an air vent fluidly connected with the sample inlet and is used to purge air from the system during sample loading, but is not necessary and can be closed for the micro- eductive mixing process. Port 55 may be replaced by a waste collection reservoir.
  • the fluid circuit is comprised of ports 54 and 55, channels 48, 49, 50, 51, 52, 53, fluid chambers of the bellows pumps 41, 42, and assay chamber 43.
  • Pneumatic channels and air pressure ports off-card are used to drive diaphragm 57 of bellows pump 42 and diaphragm 58 of bellows pump 41.
  • Air vents 56, 59 equilibrate pressure above the diaphragm of bellows pumps 41, 42. Not shown is a waste reservoir. Pneumatic valves 46, 47, pumps 41, 42, pneumatic actuators, and waste structures of representative microfluidic devices 1, 20 and 40 are described in more detail in the following figures.
  • FIG. 4 shows a pneumatic "peanut" valve 70 schematically and its action is shown in cartoon form in FIGS. 5 A and 5B (upper panel- valve open; lower panel- valve closed).
  • microfluidic channels 71, 72 entering from the right and upper left enter a microcavity 73 (100-500 microns in diameter) at two vias 74, 75 capped by a flexible polyurethane or PET diaphragm layer 76 that is laser welded to the plastic body 77 of the valve.
  • An elastomer is preferred for the diaphragm.
  • Negative pressure via control pneumatic actuator channel 79, pulls the flexible layer up and away from the step vias 74, 75 in the fluid path, opening a path for fluid to flow from the left to right microchannels 71, 72 as shown.
  • the pneumatic actuator circuit is also a microfluidic structure, and is built into the card. Valves70 can be ganged or operated independently from positive and negative air pressure sources off-card. Generally this is handled by computer, but manual activation may also be used. This valve structure is used for stop flow in the Microflow micro fluidics assay instrument (Micronics, Redmond Wash. USA). Note that the fluid path is isolated so that no user contact with the test fluids is possible following entry of the sample into the valve body and that the default position of a valve with elastomeric diaphragm is "closed".
  • FIG. 6 is plan view of a microfluidic bellows pump 90.
  • the pump works analogously to a diaphragm pump as can be seen from FIGS. 7A and 7B .
  • the pump cavity is divided into two approximately equal volume chambers, a "lower” half-chamber 97 and an "upper” half-chamber 98, the lower half-chamber 97 for containing fluid, and the upper half-chamber 98 for pneumatic actuation.
  • "Upper” and “lower” chambers can be inverted or stood on end without limitation.
  • bellows pump flexible diaphragm 93 bisects the pump cavity in a coronal plane.
  • Flexible diaphragm 93 is optionally an elastomer.
  • pneumatic actuator channel 94 connecting with upper half-chamber 98, valve 95, and pneumatic pressure source 96 are used to control the pump.
  • the enclosing flexible layer top, bottom, or top and bottom of the card
  • fluid is displaced from the bellows reservoir and escapes through fluidly connected microchannels.
  • Check valves can be positioned in the microchannels on either side of a bellows pump to force directional flow. Alternatively, check valves may be used to fully seal the dual pump subassembly during eductive mixing. In eductive mixing, air pressure in actuator channel 94 of upper half-chamber 98 is pulsed, driving flexible diaphragm 93, which in turn drives fluid in the lower half-chamber 97. The mathematics of the operation are described in more detail in a simplified schematic in FIG. 9 .
  • Bellows pump materials may be varied to select the required stiffness and elasticity. Elastic layers generate positive pressure when the pump surface is depressed and negative pressure when the surface is released. We have found that both positive and negative pressure-induced flows, away from or toward the bellows pump respectively, can be advantageously used in operation of microfluidic device based assays. Note again that the user is isolated from contact with the sample and reagent fluids.
  • the microfluidic device is packaged in the form of a kit, and contains on-board reagents sufficient for analysis of a single clinical test specimen.
  • kit-packaged cards are single-entry (i.e., a single entry to introduce the sample is made) and the card is otherwise sealed and self-contained.
  • FIGS. 8A and 8B shows a cross-section through a waste receiving reservoir or apparatus 100 designed to prevent egress of contaminated sample and reagents from the microfluidic assay card. Waste entering through waste fluid channel 104 is imbibed into bibulous material (an absorbent pad or bat 101) positioned in the waste receiving reservoir in the plastic body of the card 102.
  • the pad 101 swells as liquid is absorbed, as depicted in FIG. 8B .
  • the waste receiving reservoir has a waste fluid channel aspect (here upper) and a vent aspect (here lower).
  • Flexible or elastic film layer 103 separates the waste fluid channel aspect from the vent aspect of the waste receiving reservoir.
  • a vent 105 is provided in the waste reservoir so that as the inner membrane expands, air pressure is equalized in the reservoir. Note that the vent may be supplied with a liquid barrier filter or membrane 106 to prevent egress of fluid as an additional safety measure.
  • a flexible layer covering the waste receiving reservoir allows the reservoir to serve as a bellows pump.
  • reagent is premeasured into a blister pouch in a sealed cavity on the card.
  • a sharp, positioned under the blister pouch is contacted with the pouch when finger or mechanical pressure is applied to the opposing film, rupturing the pouch and releasing the contents.
  • the chamber is fiuidly joined with a microfluidic channel so that the reagent is simultaneously released and forced by the pressure through the device in the required direction.
  • Color development reagent for example, or antibody reagents, may be safely stored in on-board blister pouches for use in the assay or added through a reagent port.
  • on-board blister pouches By use of on-board blister pouches, the user is isolated from contact with biologicals or chemicals used in the assay.
  • FIG. 9 demonstrates a "first cut” design calculation for eductive mixing.
  • FIG. 9 is intended to be read with FIG. 7 and FIGS. 1 , 2 and 3 .
  • FIG. 9 shows a lower bellows pump cavity 140, in explanation the "lower half-chamber” or fluid side of the pump.
  • FIG. 7 shows a complete sectional view of a bellows pump with diaphragm 93 and both upper and lower half-chambers 97, 98.
  • FIGS. 1-3 show how such bellows pumps 4, 8, 24, 25, 41, 42 are used in pairs.
  • the lower half-chamber 140 of the bellows pump cavity is modeled as a cylinder with a flexible cover diaphragm 141, and with base and walls.
  • the baseplate and coverplate 21 of the card body 20 are not shown here so that the internal fluid voids are more clearly represented.
  • the upper half of the bellows pump cavity (see FIGS. 7 A, 7 B element 98) and pneumatic actuator circuit 94 are also not shown for clarity.
  • the flexible cover diaphragm 141 must be compliant, as illustrated in FIG. 7 , and is preferably elastic and durable.
  • the cylinder has height HI, diameter DI, and nominal volume VI 142.
  • the working diameter of the bellows diaphragm is an "effective diameter” based on compliance of the cover film and the pneumatic pressure, and therefore the actual displacement or “stroke” volume Vs of the flexible membrane from its resting to its fully compressed and extended position (convex deformation downward) is typically less than the nominal volume of the half- chamber VI 142 due to imperfect compliance and dead volume. Because pneumatic pressure is used instead of mechanical actuation, stroke volume is improved due to reduction of dead volume.
  • the fractional effective fluid stroke volume (Vs/VI) of the pneumatically actuated bellows pump is greater than 0.5, preferably greater than 0.8.
  • Vx we also call attention to the active downstroke volume Vx, which is in fact may be greater than the displacement volume Vs because the stroke typically begins with the flexible cover distended (concave deformation upward) due to priming with fluid on the power stroke of the companion or tandem bellows pump, keeping in mind that these pumps are always used in pairs as shown in FIGS. 1-3 .
  • the tandem diaphragm in the other chamber On the active power stroke of one diaphragm, the tandem diaphragm in the other chamber will become distended during its passive fill half cycle, and can then deliver a greater active stroke volume Vx on its power downstroke half cycle.
  • Vx may be double Vs.
  • the method of use involves depressing the flexible membrane of one pump, then the other, in alternation, so as to cause reciprocal flow back and forth through a central chamber separating the dual pump chambers.
  • the total volume exchanged may be the sum of the active volumes of both pump chambers.
  • one pump is typically active and one passive during each half cycle, alternating in tandem, and thus further differentiating the mechanism from a pair of pump chambers in series.
  • the pneumatic actuator may thus be directed to one of the two diaphragms, and the other diaphragm can be configured to follow passively, its upper half-chamber vented to atmosphere.
  • the fluid systems can be completely closed during the mixing operation (i.e., without venting on the fluid side), a useful precaution against accidental operator exposure to the contents of the device and against formation of aerosols.
  • Flow constrictive" or “flow focusing” aperture 143 has width YI, depth ZI, and length LI. As shown, YI is a smaller than ZI, but this is not required.
  • the purpose of the flow constriction is to accelerate the fluid in the aperture's cross sectional area so that the Poiseuille or parabolic flow regime characteristic of this scale of device is disrupted and microeddies, turbulence, and fluid jets form, emulating the action of a Penberthy eductor at a microscale.
  • Mean velocities of 10-500 mm/sec are sought for immunoassay development as described here, and the aperture dimensions, active downstroke volume, and pressure pulse PI on the flexible layer is configured to produce nominal average velocities in the range of 10 to 500 mm/sec, more preferably 20 to 200 mm/sec and most preferably 25-100 mm/sec, and increasing the apparent Reynold's number at the plume fringes.
  • aperture dimensions and mixer conditions are configured to correspond to shear rates (flow linear velocity over dimension or diameter) in the range of 5 sec -1 to 500 sec -1 . Shear rates of up to 3000 sec -1 are contemplated. Note that the shear rate may be calculated relative to Y as the critical dimension or Z as the critical dimension, where the critical dimension is generally the narrowest point of passage of the fluid and the flow velocity is determined by the pump chamber volume, diaphragm diameter D 1 and stroke rate.
  • the aperture may be generally rectangular in cross section, generally circular in cross section with diameter Y, or any convenient shape. Y may optionally equal Z; Z may optionally equal the height of the pump chamber HI.
  • Aperture dimension LI is generally selected to focus flow and is in the range of a few micrometers to a few millimeters.
  • Ratios ZI/DI and YI/DI are generally determined to be less than 0.5, more preferably less than 0.25, and preferably less than 0.1.
  • Design optimization involves reducing both Y and Z while increasing stroke volume. Improved mixing characteristics are thus obtained by optimizing both the aperture and diaphragm configuration.
  • a more complicated design calculation, also modeling viscosity, density and localized turbulent flow, may also be performed, or the design may be optimized empirically. Note that a critical lower limit in aperture dimension is crossed when wall shear results in destruction of assay targets or reagents, as is again best determined empirically.
  • a microfluidic card 150 for use in an agglutination assay.
  • three matching microfluidic channels distribute the sample fluid at a controlled rate into three channels of the assay 152, 153, 154.
  • reagent reservoirs at the top of the card 155, 156, 157 up to three reagents may be introduced into separate analytical channels. More or fewer channels may be used.
  • the serpentine microchannels 158, 159, 160 are primed manually or mechanically with the bellows pump shown near the bottom of the card, which may also be a sealed waste reservoir 161, as described in FIG. 8 . Vent 163 balances pressure in the waste reservoir.
  • the vent 163 may contain a water impermeable:gas permeable filter barrier.
  • the vent exit may also contain a valve (not shown) to assist in priming with bellows pump 161 fitted with an elastic cover layer in the coverplate.
  • the results of the agglutination are read in a window for the test field 162 (see result in FIG. 12 ).
  • Reagents with beads or cells coated with an affinity capture agent may be used to assist in detecting agglutination.
  • a single reagent can be introduced into the "sample” reservoir and multiple samples can be introduced into the "reagent" reservoirs at the top of the card.
  • Various permutations of the means and order of sample and reagent addition are easily contemplated. These agglutination assays may be used to diagnose infectious disease or to do crossmatches or to detect drugs.
  • FIGS. 11 and 12 are endpoint data for assays performed as described in the Examples discussed below.
  • Microfluidic channels built by layered sheet construction typically have square cross-sectional profiles.
  • the channel diameters are adjusted to permit passage of individual beads and bead agglomerates.
  • Bead diameters are typically in the range of 1-100 microns, more preferably 2-15 microns (mean size) and the channel diameter must be sized accordingly.
  • Microchannels constructed of layers formed by extrusion molding may have more rounded channel profiles and a radius on each "via".
  • the internal channel surfaces of injection molded parts are also somewhat smoother.
  • the flow characteristics of the channels are significant because of the profound surface effects in the microflow regime. Surface tension and viscosity compound surface roughness effects. Channel surfaces may be passivated as required.
  • the most narrow dimension of a channel has the most profound effect on flow. It follows that flow in channels that are based on square or circular cross-sectional profiles is controlled by the diameter or diagonal width, and design is typically varied to take advantage of this behavior. Reduction of taper in the direction of flow leads to a capillary effect for diameters below 200 microns. Conversely, opening up a channel to form a bulb stops flow unless pressure is applied. Vias in a channel can be designed to promote directional flow, a sort of solid state check valve.
  • Agglutination is a well known way of detecting an antigen:antibody reaction. Agglutination that is detectable by visible inspection is preferred. Of these visible means, colored microparticles, particularly what are known as "beads" in the art, are more preferred.
  • Colorable beads or particles and colorable latex beads are also known in the art and useful as detection means for immunoassays (see, for example, U.S. Pat. Nos. 4,373,932 and 4,837,168 ). Colored reagent solutions may also be used to enhance the visual characteristics of agglutination and aid interpretation. For visualization of agglutinations of very small particles, magnifying lens windows may be formed in the coverplate or faceplate of the device.
  • beads may be "tagged" with labels to improve the sensitivity of detection.
  • Fluorescent molecules such as the rhodamine, fluorescein, or umbelliferone series, employed by themselves or with a quencher molecule, may be used (see, for example, U.S. Pat. Nos. 3,996,345 and 4,366,241 ,).
  • Chemiluminescent molecules such as luminol, luciferin, lucigenin, or oxalyl chloride can be used as a signal means (see, for example, U.S. Pat. No. 4,104,029 ).
  • Enzymatic systems that react with a colorless substrate to give a precipitated colored product, such as conjugated horseradish peroxidase with aminoethylcarbazole and hydrogen peroxide as substrate are also useful as signal means.
  • Single and dual labeling may be used on a single bead species, or optionally, multiple bead species, each containing an individually recognizable signature of a combination of chromophores or fluorophores may be used.
  • the particles may be modified with certain specific affinity binding molecules to form conjugated particles.
  • Immunoreactive affinity binding molecules include antigens, haptens, aptamers, antibodies (primary or secondary), and complexes thereof, including those formed by recombinant DNA methods, in hybridomas, or by peptide synthesis.
  • Other common agglutination detection systems based on affinity capture include but are not limited to, biotin and avidin (or derivatives thereof), biotin and streptavidin, carbohydrates and lectins, effector and receptor molecules in general, and the nickekhistidine system.
  • the affinity capture molecule for example an antigen or agglutinin antibody, may generally be attached to the bead using any of a variety of well-known techniques.
  • covalent attachment of the specific binding members to the detection probes may be accomplished using carboxylic, amino, aldehyde, bromoacetyl, iodoacetyl, thiol, epoxy and other reactive or linking functional groups, as well as residual free radicals and radical cations, through which a protein coupling reaction may be accomplished.
  • FIGS. 13A - B are a plan and cross-sectional view of a first apparatus for staining a glass slide, the apparatus having dual bellows pumps acting in tandem to produce reciprocating flow through a sealed reaction chamber formed on the face of the glass slide.
  • FIG. 13C is a detail showing placement of the edge seal member.
  • glass slide is indicated any of the generally planar substrate members as are commonly used for microscopy, including histopathology, oncology and cytology, for array hybridization, for proteomics, for high throughput screening, and so forth, without limitation.
  • the inventive apparatus 200 is formed on a baseplate 201, which may be built up from layers to enclose fluidic circuits or may be injection molded in one or more pieces.
  • the baseplate is made of plastic, although one may be machined from stainless steel, for example, if desired.
  • a glass slide 202, with specimen(s) mounted thereon, is affixed to the baseplate using an edge gasket 203 as will be shown in FIGS. 13B and 13C in more detail.
  • the specimens 204 in this illustration are on the underside of the glass surface.
  • An aperture on the top web of the edge gasket defines an observation window 205 with viewing area 206 through the upper surface of the glass slide, as may be useful for photography or microscopy.
  • a recess under the glass slide forms a sealed reaction chamber 207.
  • An observation window may also be formed in the baseplate member for transmitting light through the reaction chamber.
  • a first bellows pump 212 and a second bellows pump 214 are used to propulse fluid back and forth through the sealed reaction chamber, as will be described in more detail below.
  • the glass side 202 is shown overlying a sealed reaction chamber 207 formed as a recess under the glass slide.
  • the glass side rests in juxtaposition to a raised platform 208 defined by outside lateral walls 209 that join to the baseplate 201.
  • the recess is defined by inside lateral walls 210 and a slab 211 forming the floor of the recess.
  • the slab may optionally be sloped or contoured and may be provided with a drain for draining fluid from the sealed reaction chamber 207.
  • the sealed reaction chamber is a shallow tray extending across the area of the glass slide having specimens mounted thereon, where the depth of the tray is typically in the range of 5 to 100 micrometers.
  • Reagent fluid is forced from bellows pump 212 through a fluidic connection to the reaction chamber by a downward stroke of diaphragm 212a. Once air is purged from the internal hydraulics, fluid filling bellows pump 214 may be returned to bellows pump 212 by a downward stroke of diaphragm 214a. Valving is not shown for clarity. This process of sequential actuation of the diaphragms 212a and 214a may be repeated to generate a reciprocating flow between the tandem bellows pumps (212, 214) through the reaction chamber, thus ensuring that the specimens are fully contacted with the reagent fluid.
  • reaction chamber Because the dimensions of the reaction chamber are microfluidic in depth, mixing in the z-direction is primarily by diffusion, and is relatively rapid at depths of 5 to 100 micrometers.
  • the pump action ensures that fluid in the chamber does not become locally depleted of reactants, fresh fluid is periodically washed through the chamber as required to complete the reaction of the reagent with the specimens.
  • the "x" and "y" dimensions in the chamber may be configured to support high-throughput screening or smaller scale experiments as needed. If desired multiple copies of the apparatus 200 may be operated in tandem, either by hand or using an automated workstation.
  • probes may be introduced into the chamber to selectively bind with the arrays and then light up target molecules in the array.
  • specimens 204 are tissue sections
  • stains or antibodies may be introduced into the chamber to selectively bind to certain cells, and those cells may then be visualized.
  • fluorescent probes are used, as in FISH (fluorescent in-situ hybridization), allowing researchers to track biological activities in situ.
  • sequencing reactions such as polony sequencing may be performed in chambers of this kind.
  • the thickness of the viewing window may be selected as required to interface with an optical package, and image analysis is readily accomplished using digital pictures of the viewing area.
  • the edge gasket 203 is formed to enclose a lip 215 formed on the raised platform 208. This is shown in more detail in FIG. 13C .
  • Slide 202 is sealedly clamped to lip 215 using gasket 203.
  • Shown are outside lateral wall 209 of the raised platform and inside lateral wall 210 of the internal recess forming the sealed reaction chamber 207.
  • Fluidic channel 216 formed between the outside lateral wall 209 and inside lateral wall 210 communicates fluidically between the bellows pump and fluid reagent reservoirs depicted in FIG. 13B and the sealed reaction chamber 207. Fluid entering the reaction chamber at 217 ( FIG. 14 ) cannot escape unless provided with an exit or vent.
  • the edge gasket member is a formed article, generally a soft and pliant but tough material such as a silicone rubber or a vinyl rubber or other elastomer.
  • a "u-shaped" trough extending the full internal edge of the gasket is slipped over the slide and lip 215 to make the seal. This simplifies the hydraulics and relieves bending of the slide as has been observed with other clamping systems, but requires facing the specimens downward into the reaction chamber.
  • a rigid clamp can be affixed to reinforce the edge gasket 203 illustrated here.
  • the rigid clamp will generally follow the shape of the edge gasket but be tightened over it the soft clamp if needed to prevent leaking of the reaction chamber under pressure.
  • Other clamping systems may be used if desired.
  • heating devices or Peltier chips may be placed in the raised platform and temperature controlled within the reaction chamber.
  • the effect of the heating devices is to control the temperature of the liquid, and advantageously the glass slide is not the conduit whereby heat is conveyed to the chamber, thus minimizing risk of damage to the specimens by overheating or freezing.
  • the sealed reaction chamber can be formed around a segment of a glass slide by inserting the slide through a slit or cutout on one end (or both ends) of the gasket. This is useful, for example, when labeling on a tab at one end of the slide is to be protected or when an electrical junction is required for mounting a wire harness to one end of the slide.
  • the resulting electrical connection(s) may be useful for powering an electrode array in the reaction chamber or for operating a thermistor, while not limited thereto.
  • FIG. 14 is an exploded view of the apparatus of FIG. 13 .
  • Baseplate 201 supports a pair of bellows pumps 212, 214 for pumping fluid through reaction chamber 207, shown here exposed so that the recessed tray forming the bottom of the reaction chamber is readily observed.
  • Fluid port 217 is representative of connections to fluidic circuitry embedded in the baseplate.
  • the recessed tray may be sloped or graded to encourage draining of reagent fluids during rinsing cycles.
  • the recessed tray may also contain heating or cooling elements if desired.
  • the slide 202 is supported on the raised flat ledge 218 surrounding the recessed tray, and the edge walls are generally conformed dimensionally for a good fit.
  • a guide lip may be used if needed so that the slide is readily registered on the platform top surface.
  • the edge gasket 203 is fitted around the edges of the slide and under outside lip 215 so as to seal the slide against the recessed tray, thereby forming a sealed reaction chamber 207.
  • the reaction chamber is dissassemblable by reversing these steps, for example when it is desired to remove the slide for subsequent examination or archiving. Alternatively, the entire assembly can be archived as a single unit.
  • the cylindrical housings of the diaphragm pump can be made to fit into mated recesses in the bottom of the base plate, permitting stacks of apparatus to be shelved.
  • the slide is commonly supplied by the end user and may be or not be supplied as part of the reactor apparatus.
  • FIG. 15 is a schematic view showing dual bellows pumps and fluid flows in the enclosed chamber. Arrows indicate reciprocating bidirectional flow. A downward stroke of the diaphragm of bellows pump 212 results in flow toward bellows pump 214. When a downward stroke of the diaphragm of bellows pump 214 is caused, flow returns in the direction of bellows pump 212.
  • a downward stroke of one bellows pump may be accompanied by an upward stroke of the opposing bellows pump, doubling the energy of the pumping action.
  • a single pump may be actuated at a time, and the other pump slaved to the action of the active pump.
  • FIG. 16 is a plot showing alternating polarity of the strokes of a bellows pump diaphragm.
  • the second bellows pump is operated in tandem by application of a synchronous inverted signal.
  • the signal may be pneumatic or electrical. Operation of pneumatic control systems has been described above. Electrical actuation of magnetically controllable or electrostatically controllable diaphragms is also known in the art and finds use in the diaphragm actuation systems of the invention.
  • the diaphragm pumps may also be fluidically connected to external fluidic circuits, such as for pumping reagents from a fluid reservoir into the reaction chamber.
  • Port 219 may connect to an external circuit or to a reagent reservoir.
  • FIGS. 17A - C are diagrams showing different configurations and the effect on fluid advancing through the sealed reaction chamber.
  • An issue in microfluidic fluid systems is meniscus control during wetout. The balance of flow in these systems typically is described by a capillary component and a drag component as analyzed in co-assigned US Pat. Publ. No. US2010/0112723 .
  • Surface active agents, surface modification, geometry, and surface features are useful to control wetting.
  • Vertical orientation of the apparatus so that the reaction chamber is primed from below is also useful in avoiding uneven wetout and residual entrapped bubbles.
  • the devices,systems, and apparatus of the invention unlike some prior art devices, may be operated in either the horizontal, vertical or inverted position.
  • FIGS. 18A - B diagrammatically represent different configurations of paired bellows pumps and flow patterns in the sealed reaction chamber.
  • the use of independently controllable pairs of bellows pumps provides a robust and flexible platform for mixing thin fluid layers having a microfluidic characteristic dimension.
  • FIG. 18A a system 220 with eight independently controllable bellows pump units 221 connected fluidically to sealed reaction chamber 207 having samples 204 disposed on a glass substrate are shown mounted in an integrated baseplate member 201.
  • FIG. 19 depicts yet another system 230 configured with ten paired bellows pumps for achieving coordinated complex mixing patterns so as to fully contact the specimens 204 with the fluid reagents of the process.
  • FIG. 20A is a schematic of multiple flows in a sealed reaction chamber. Flows are directed so as to produce overlapping fields of laminar flow that coalesce into a bulk flow from left to right in sealed reaction chamber 207.
  • FIG. 20B is an alternate form of an injector port 240 as may be supplied with tubulation for attachment to a bellows pump. Pulses of fluid entering the chamber 207 result in the fluid flow of FIG. 20A . Also shown is an alternate barb clamp system for use in sealing slide 202 over the chamber. In this case, the slide is upright in the chamber so that the specimens are bathed in fluid filling chamber 207.
  • FIGS. 21A - 21F depict means for clamping, means for sealing, and means for releasing a cover plate of a sealed reaction chamber from a substantially planar substrate to which it is affixed.
  • FIG. 21A illustrates an O-ring 251 inserted between a glass slide 202 and a coverplate for forming a sealed reaction chamber 207.
  • a variety of compliant gasket materials known in the art may be used for internal seals.
  • FIG. 2 IB depicts an adhesive seal strip 252a for forming a seal around a sealed reaction chamber 207 and slide 202. As shown here the chamber is filling with fluid 207a from an external port.
  • FIG. 21C depicts a second adhesive strip, where the dimensional geometry of the sealed reaction chamber 207 is ensured by a hard lip contacting the glass slide 202.
  • FIG. 21D depicts an end seal 253 formed of a compliant gasket material.
  • FIG. 21E shows a clamping feature 254 with release 255.
  • FIG. 21F shows a fully enclosing chamber for receiving a glass slide 202.
  • Spacers 256a and 256b define a headspace volume 258 that contacts both the top and the bottom of the slide.
  • FIGS. 22A and 22B depict lip seals formed by micromolding of thermoplastics.
  • the plastic lip yields under pressure to form a contact seal with the glass slide 202, thereby sealingly enclosing a reaction chamber 207.
  • FIGS. 23A and 23B shown is a representative arrangement 300 of the invention having a detachably insertable slide chamber minicassette and multiple reagent reservoirs with waste storage capacity on board.
  • the apparatus is seen to comprise a baseplate 301 module (also termed a microfluidic card) and a reversibly engageable slide chamber minicassette 302. Glass slide 303 is shown partially mounted in the minicassette subassembly 302.
  • a baseplate 301 module also termed a microfluidic card
  • Glass slide 303 is shown partially mounted in the minicassette subassembly 302.
  • the glass slide 303 is shown to be angularly positioned for insertion into a latching barb mechanism 312 of the cassette housing 317.
  • a compliant internal gasket 311 forms a seal around the sealed reaction chamber 310 when the slide is click locked in place.
  • Reagent fluids are admitted through nipples 316a and 316b as described below.
  • Other means for sealing and clamping, for example as described in FIGS 21 and 22 may also be used.
  • Baseplate module 301 is comprised of dual bellows pumps (322, 324), reagent reservoirs or ports 307a-c, and waste fluid reservoir 304 with vent 308.
  • the slide minicassette may be exchangeably plugged into docking bay 305 on the baseplate and moved from one baseplate to another if desired, for example if a complex reaction protocol is executed.
  • the baseplate is loaded with reagents through reagent ports 307a through 307c, which are fluidly interconnected with the slide cassette via the bellows pumps and nipples 316a and 316b on the slide cassette, which sealedly engage ports 306a and 306b of the docking bay when the cassette is inserted.
  • Bellows pumps are used to provide the fluid motive force for loading reagents and for circulating fluids through the sealed reaction chamber 310.
  • the bellows pump diaphragms 322a and 324a may be pneumatically actuated, or actuated electronically using solenoids or using electrostatic technologies known in the art.
  • microfluidic circuitry shown within the baseplate is made relatively simple for ease of explanation, more complex circuits may be formed by a process of laminating layers or by forming molded pieces with complex micro features and by a fusion process selected from solvent welding, ultrasonic welding, or laser welding as are known in the art.
  • the number of reagent reservoirs is sufficient, for example, for a three step staining protocol involving a staining step, a rinse step, and a counterstain step. More complex protocols can be performed with additional reagent reservoirs or with off-card reagents.
  • the reagent reservoirs are also optionally removable, and may be provided with threaded nipples for insertion into connecting fluidic channels within the baseplate so that they may be exchanged at will. In one arrangement, baseplate modules and prefilled reagent reservoirs are sold separately, or in kits.
  • FIG. 24 is a cross-sectional view of the arrangement of FIG. 23 .
  • Slide minicassette subassembly 302 is shown in a partially open view.
  • Slide 303 seals against housing 317 by a click lock clamp feature 312.
  • a soft gasket 311 is provided to ensure the internal reaction chamber 310 is fully sealed.
  • This unit is disposable or may be stored for archiving once processed. Specimen materials mounted on the inside face of the slide are subjected to reactions within the reaction chamber 310, generally by being contacted with fluid reagents introduced through ports 316a and 316b.
  • the slide minicassette 302 is configured to removably insert into docking bay 305 of the baseplate module 301, where ports 316a and 316b sealably mate with fluidic channels 306b and 306b.
  • Each fluidic channel is in communication with a bellows pump assembly 322, which includes a diaphragm member and actuation means for drawing fluid from reagent reservoir 307 and into the reaction chamber 310.
  • bellows pumps 322 and 324 operate in tandem, either by receiving synchronously inverted actuation signals so that one bellows pump is on a downstroke when the other bellows pump is on an upstroke, or the two pumps are operated in alternation.
  • the two pumps may also be operated where one pump is master and the other pump is slave.
  • This configuration is especially useful for elastomeric diaphragms because the slave pump stores stroke energy in the form of stretch of the diaphragm and releases it on the counter stroke.
  • a reciprocating flow regime can be established through the sealed reaction chamber.
  • the chamber typically has a microfluidic "z" dimension wherein diffusional transport is dominant, but the bellows pumps have been shown to be effective in refreshing the boundary layer concentrations above the unstirred layer and thus driving diffusion limited reactions to rapid completion.
  • FIG. 25 illustrates a plurality of apparatus modules 300 for use in a carousel or other automated system.
  • the modules are mounted in a vertical position to aid in purging bubbles. This demonstrates the suitability for use of the modules in operation of an automated system for processing multiple specimens in parallel.
  • a microfluidic device for ELISA immunoassay was prepared as follows:
  • a standard assay for ELISA useful as a benchmark in method development, involves detection of immobilized human IgG on a solid substrate, followed by blocking and detection of the IgG with biotin-labelled anti-human antibody. The biotin in turn is detected with enzyme-labelled streptavidin.
  • TMB (3,3', 5,5'-Tetramethylbenzidine) in Citrate/ Acetate Buffer was used as the chromogen. Results are shown in the close-up photo insert of FIG. 11 .
  • the chamber is described in FIG. 3 and FIG. 9 . Note the blue color characteristic of TMB precipitation in the test zone labelled IgG (upper). IgM (lower) was used as a negative control.
  • test pads Three test areas are negatively masked on a sheet of polystyrene corresponding to a window in a microfluidic device and the plastic is plasma activated.
  • the following antigens, diluted to 2-5 ug/mL, are then immobilized on one each of the test pads:
  • test strip is then blocked and assembled in a sealed microfluidic assay device of FIG. 2 .
  • patient serum (1:10 dilution in 180 ⁇ L PAABS buffer composed of PBS, 1% BSA, 0.02% sodium azide pH 7,4) is pipetted into the completed microfluidic device through the sample port.
  • the serum is allowed to wet the test pads and the device is incubated 5 min with slow mixing.
  • the test strip is then rinsed I x with PAABS.
  • a solution of Goat anti-human IgG and Goat anti-human IgM (2: 1) at appropriate dilutions in PAABS (200 ⁇ L) is added through the sample port and allowed to incubate on the test strip at RT for 20 min.
  • test strip is rinsed 1x and drained.
  • Detection antibody a solution of anti-goat IgG conjugated with glucose oxidase, is then applied and incubated at RT for 10 min.
  • the test strip is again rinsed and drained.
  • Development is performed with a solution of nitroblue tetrazolium dye (NBT) in TRIS buffer pH 9.5.
  • NBT nitroblue tetrazolium dye
  • Influenza undergoes a rapid clinical course.
  • respiratory epithelial lavages contain infectious agent, non-infectious nucleocapsid and envelope debris, and Influenza antigen:lgA complexes.
  • the diagnostic approach taken here involves detection of IgA specific to the Influenza virus. Detection of antibodies is described here.
  • HPLIV horseradish-peroxidase labelled Influenza virus
  • the method cited by Nielsen is followed [ Nielsen, S L et al. 1986. Detection of Immunoglobulin G Antibodies to Cytomegalovirus Antigens by Antibody Capture Enzyme -Linked Immunosorbent Assay. J Clin Microbiol, December 1986, p. 998- 1003 ], but with Influenza virus particles purchased from Fitzgerald Industries (Concord Mass., USA).
  • a micro fluidic device is prepared by first immobilizing monoclonal mouse anti-human IgA on the surface of a test strip and blocking with casein-tween blocking solution. The test strip is mounted in a cavity of the device before final assembly. During assembly, the sample reservoir (ie.
  • HMLIV reagent in 50 ⁇ L TBS 1% bovine serum albumin 0.1% Tween 80 (TBSBT) and dried in place under vacuum.
  • TBSBT bovine serum albumin 0.1% Tween 80
  • Coarsely filtered saline nasal lavage, 2 mL, is buffered with 0.2 mL TRIS to pH 7.4, and the entire volume is transferred to the sample reservoir of the microfluidic device.
  • the material is incubated in place for 2 min to fully dissolve the antigen-conjugate. Sample solution is then passed back and forth across the test field capture site, using the dual bellows system to generate slow reciprocal flow for 2 min.
  • HRP-labelled virus particles are coated by any IgA antibodies in the sample, and any IgA in the sample is captured by the excess of anti-lgA immobilized on the test strip.
  • the device is washed 3x with TBSBT buffer and the rinses drained into the waste reservoir.
  • An adjoining blister pouch (CDRP) fluidly connected to the test chamber contains the color developing reagent. Pressing on a diaphragm overlying the CDRP ruptures the pouch and releases color developing reagent into the test cavity. Development of a blue color precipitate on the test strip is indicative of an immune response, and confirms the presence of immobilized IgA complexes with the HRP-complexed influenza antigen. All mixing and wash steps use eductive mixing.
  • the microfluidic device used in this assay is that shown in FIG. 7 .
  • This card can be used to test two or three reagents against a common liquid bead reagent.
  • anti-human IgG Fc fragment-specific biotin conjugated antibody Pierce
  • PBS was used as a negative control.
  • Blue streptavidin-coated beads (Seradyne, 1% solids) suspension was diluted by adding 3 ⁇ L of the resuspended beads to 50 ⁇ L PBS.
  • the bead solution was placed in a well communicating with each of the test channels.
  • Antibody solution and PBS were placed in test wells at the top of the card.
  • PBS was placed above the left and right channels; antibody solution was placed above the center channel. Using suction pressure generated by a bellows pump, the test solutions and reagent beads were brought into descending serpentine channels in the card and allowed to react as flow continued. There was an immediate strong agglutination reaction in the channel containing streptavidin-coated beads and antibody biotin conjugate. The PBS channel was negative for agglutination. A close up photograph of the results in an assay window is shown in FIG. 12 .
  • Clean catch urine is collected for the test at the point of care. Specimens with a specific gravity greater than 1.020 are acceptable for the test.
  • the micro fluidics card of FIG. 10 is readily adaptable for the test. Urine is placed in the upper center well. Positive and negative test fluids are place in the side wells. Anti-human BTA IgG conjugated with latex beads is placed in the lower reagent well. The bellows pump is used to initiate flow and mixing of the sample and reagent streams. As each fluid mixes and incubates in the serpentine channels, agglutination of the latex beads observed through the optical window over the center channel indicates a positive immunodiagnosis for the presence of the tumor antigen.
  • the bead reagent fluid is optionally colored to aid the user in following the progress of the assay.
  • Diarrhoeal fluid 20 mL, which is mostly electrolyte with some mucous, is collected with sterile technique and transferred to a 50 mL polypropylene centrifuge tube. 20 mL of TRIS buffer 0.1M pH 7.0 containing 0.01% thimerosal is added. After light centrifugation in a tabletop centrifuge at 5000 rpm for 10 min to remove grossly visible detritus and mucous strands, the supernatant is decanted into a clean sample container for testing. This solution potentially contains infectious agent and is handled with appropriate precautions.
  • the pretreated sample is analyzed in a diagnostic card of the present invention. Preparation of the card is as follows.
  • Cutouts on thin layers of PET are prepared by laser lithography. Latex beads (Seradyne blue) with antibody to the infectious agents of interest are obtained and resuspended in Citrate 1% BSA 0.1 % Triton-X 100 pH 7 lyophilization buffer. The bead suspension is spotted or otherwise applied in the serpentine channels of the card at a concentration sufficient for the assay and is then lyophilized in place. Tests show that this protocol results in a dry bead layer that is readily solubilized by the sample fluid.

Claims (15)

  1. Vorrichtung (200) zum dichten Einschließen eines ersten Aspekts eines Substratelements (202)
    in einer Reaktionskammer (207), wobei die Vorrichtung (200) umfasst:
    a) ein Basisplattenelement (201) mit einer ersten Oberfläche, wobei die erste Oberfläche eine erhöhte Plattform (208) umfasst, die mittig darauf angeordnet ist,
    wobei die Plattform (208) eine obere Oberfläche aufweist, die eine flache Kante (218) bildet, die so bemessen ist, dass sie den ersten Aspekt des Substratelements (202) in Kontakt mit deren oberen Oberfläche aufnimmt,
    sowie Außenkanten und äußere Seitenwandflächen (209) um diese herum,
    wobei die obere Oberfläche durch eine Aussparung unterbrochen ist, die durch Innenwände (210) mit einer Höhe von 5 bis 100 Mikrometern definiert ist,
    eine vertiefte Platte (211), die die Unterkanten der Innenwände (210) verbindet,
    und die flache Kante (218), die die Oberkanten der Innenwände (210) und die Außenkanten der Plattform (208) verbindet,
    wobei die flache Kante (218) eine harte Unterstützung zum Tragen des ersten Aspekts des Substratelements (202) darauf bildet,
    wodurch eine Reaktionskammer (207) mit Kopfraumvolumen zwischen der vertieften Platte (211) und dem ersten Aspekt des Substratelements (202) gebildet wird, wenn dieser an der flachen Kante (218) abgedichtet ist;
    b) ein Dichtungselement (203), das an den Außenkanten der erhöhten Plattform (208) angebracht ist, das eine auf der erhöhten Plattform gebildete Lippe (215) umschließt, wobei das Dichtungselement (203) konfiguriert ist, das Substratelement (202) abdichtend an der Lippe zu klemmen, und
    c) eine erste Balgpumpe (212) und eine zweite Balgpumpe (214), wobei die erste Balgpumpe (212) eine erste fluidische Verbindung zu der Reaktionskammer (207) und die zweite Balgpumpe (214) eine zweite fluidische Verbindung zu der Reaktionskammer (207) aufweist, wobei mindestens eine der ersten und zweiten Balgpumpen (212, 214) eine oder mehrere fluidische Verbindungen zu einem oder mehreren außerhalb der Reaktionskammer (207) angeordneten Reagenzbehältern oder Öffnungen aufweist.
  2. Vorrichtung (200) nach Anspruch 1, wobei die Balgpumpen (212, 214) pneumatisch angetrieben sind und einen positiven Hub und einen negativen Saughub aufweisen.
  3. Vorrichtung (200) nach Anspruch 1, worin eine wechselseitige Strömung zwischen der ersten Fluidverbindung und der zweiten Fluidverbindung zu der Reaktionskammer durch wiederholtes Betätigen der ersten und zweiten Balgpumpen (212, 214) durch abwechselndes Anlegen eines Überdruckimpulses an jede der Balgpumpen getrieben werden kann.
  4. Vorrichtung (200) nach Anspruch 3, wobei eine wechselseitige Strömung zwischen der ersten Fluidverbindung und der zweiten Fluidverbindung zu der Reaktionskammer durch Betätigen der ersten und zweiten Balgpumpen (212, 214) durch Anlegen eines Überdruckimpulses an die erste Balgpumpe (212) und eines Saugdruckimpulses an die zweite Balgpumpe (214), und dann Umkehren des Drucks der an jede Balgpumpe (212, 214) angelegten Impulse, getrieben werden kann.
  5. Vorrichtung (200) nach Anspruch 1, wobei die Balgpumpen magnetisch antreibbar sind und einen positiven Pumpenhub und einen negativen Pumpenhub aufweisen, und ferner, wobei eine wechselseitige Strömung zwischen der ersten Fluidverbindung und der zweiten Fluidverbindung mit der Reaktionskammer (207) durch Umkehrung der Polarität eines ersten Pumpenhubs der ersten Balgpumpe (212) und eines zweiten Pumpenhubs der zweiten Balgpumpe (214) im Wechsel möglich ist.
  6. Die Vorrichtung (200) nach Anspruch 1, die eine Vielzahl von Paaren von Balgpumpen (212, 214) umfasst, wobei jede Balgpumpe (212, 214) des Paares eine Fluidverbindung mit der Reaktionskammer (207) aufweist, wobei die Paare angeordnet sind, um den Fluidstrom über und durch die Reaktionskammer (207) zu treiben.
  7. Die Vorrichtung (200) nach Anspruch 1, wobei die Vorrichtung (207) ein Beobachtungsfenster (205) zum Zugang gewähren auf einen Sichtbereich auf dem Substratelement (202) umfasst.
  8. Vorrichtung (200) nach Anspruch 7, wobei das Beobachtungsfenster (205) zum Zugang auf einen Sichtbereich auf dem Substratelement (202) in dem Dichtungselement (203) ausgebildet ist, und/oder wobei das Beobachtungsfenster (205) so bemessen ist, dass ein Strichcode-Etikett auf das Substratelement (202) außerhalb des Sichtbereichs aufgebracht werden kann.
  9. Vorrichtung (200) nach Anspruch 1, worin ein Beobachtungsfenster zum Zugang auf einen Sichtbereich auf dem Substratelement (202) in der Grundplatte (201) ausgebildet ist und sich durch die erhöhte Plattform (208) erstreckt.
  10. Die Vorrichtung (200) nach Anspruch 1, ferner umfassend einen Abfallauslass in Fluidverbindung mit mindestens einer der Balgpumpen (212, 214).
  11. Vorrichtung (200) nach Anspruch 1, worin das Substratelement eine Glasplatte (202) mit einer ersten Fläche ist, an die organische Substanz gebunden ist.
  12. Vorrichtung (200) nach Anspruch 1, wobei die erste Balgpumpe (212) und die zweite Balgpumpe (214) nahe der Plattform (208) angeordnet sind und/oder wobei die Plattform (208) erhöht ist.
  13. Vorrichtung (200) nach Anspruch 1, wobei das Dichtungselement (203) aus einem Elastomer, einem Vinylkautschuk oder einem Silikon gebildet ist, und/oder wobei das Dichtungselement (203) ein dehnbares Webelement zum abdeckenden und abdichtenden Umschließen des Substratelements (202) auf der Oberseite der flachen Kante (218) und ein umlaufendes Schürzenelement zum abdichtenden Eingreifen der äußeren Lippe (215) und der äußeren Seitenwandflächen (209) um diese herum umfasst.
  14. Vorrichtung (200) nach Anspruch 1, wobei ein Ausschnitt in einem seitlichen Aspekt des Dichtungselements (203) ausgebildet ist, wobei der Ausschnitt den ersten Aspekt des Substratelements (202) innerhalb der Reaktionskammer (207) und ein vorstehendes Segment des Substratelements (202) außerhalb der Reaktionskammer (207) dicht umschließt.
  15. Vorrichtung (200) nach Anspruch 14, wobei der Ausschnitt zur Aufnahme eines Trägerelements (202) oder einer Glasscheibe (202) mit einer elektrischen Verbindung angepasst ist, die auf dem vorstehenden Segment des Trägerelements (202) oder der Glasscheibe (202) montiert ist, wobei die elektrische Verbindung mit einer Schaltung innerhalb der Reaktionskammer (207) verbunden ist.
EP13703175.3A 2012-01-09 2013-01-09 Mikrofluidisches reaktorsystem Active EP2802417B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/346,615 US9056291B2 (en) 2005-11-30 2012-01-09 Microfluidic reactor system
PCT/US2013/020869 WO2013106458A2 (en) 2012-01-09 2013-01-09 Microfluidic reactor system

Publications (2)

Publication Number Publication Date
EP2802417A2 EP2802417A2 (de) 2014-11-19
EP2802417B1 true EP2802417B1 (de) 2019-05-15

Family

ID=47678998

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13703175.3A Active EP2802417B1 (de) 2012-01-09 2013-01-09 Mikrofluidisches reaktorsystem

Country Status (5)

Country Link
EP (1) EP2802417B1 (de)
JP (1) JP6190822B2 (de)
KR (1) KR102090934B1 (de)
CN (1) CN104136123B (de)
WO (1) WO2013106458A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11926817B2 (en) 2019-08-09 2024-03-12 Nutcracker Therapeutics, Inc. Microfluidic apparatus and methods of use thereof

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3549674B1 (de) 2012-12-21 2020-08-12 PerkinElmer Health Sciences, Inc. Filme mit geringere elastizität zur mikrofluidischen verwendung
JP6498125B2 (ja) * 2012-12-21 2019-04-10 マイクロニクス， インコーポレイテッド 流体回路および関連する製造方法
KR20150097764A (ko) 2012-12-21 2015-08-26 마이크로닉스 인코포레이티드. 휴대형 형광 검출 시스템 및 미량분석 카트리지
EP2994532B1 (de) 2013-05-07 2017-11-15 Micronics, Inc. Verfahren zur herstellung von nukleinsäurehaltigen proben mittels tonmineralien und alkalischen lösungen
US10386377B2 (en) 2013-05-07 2019-08-20 Micronics, Inc. Microfluidic devices and methods for performing serum separation and blood cross-matching
CA2911308C (en) 2013-05-07 2021-10-19 Micronics, Inc. Device for preparation and analysis of nucleic acids
DE102013220445B4 (de) * 2013-10-10 2016-04-07 Robert Bosch Gmbh Auslaufschutzeinheit für eine mikrofluidische Vorrichtung, mikrofluidische Vorrichtung, Verfahren zum Betreiben einer solchen Auslaufschutzeinheit und Verfahren zum Herstellen einer solchen Auslaufschutzeinheit
DE102013221525A1 (de) * 2013-10-23 2015-04-23 Robert Bosch Gmbh Analyseeinheit zur Durchführung einer Polymerase-Kettenreaktion, Analysevorrichtung, Verfahren zum Betrieb einer solchen Analyseeinheit und Verfahren zum Herstellen einer solchen Analyseeinheit
US10076751B2 (en) * 2013-12-30 2018-09-18 General Electric Company Systems and methods for reagent storage
US10634590B2 (en) * 2014-03-11 2020-04-28 Emd Millipore Corporation IHC, tissue slide fluid exchange disposable and system
WO2015161275A1 (en) * 2014-04-18 2015-10-22 Bio-Rad Laboratories, Inc. Microfluidic devices for automated assays
JP6723541B2 (ja) * 2014-05-14 2020-07-15 ゼネラル・エレクトリック・カンパニイ 撮像用マイクロ流体フローセルアセンブリ及びその使用方法
US20170122965A1 (en) * 2014-08-25 2017-05-04 Konica Minolta, Inc. Reaction method, detection method, and detection device
CN104568557A (zh) * 2014-12-22 2015-04-29 珠海迪尔生物工程有限公司 一种用于固定玻片的夹具
US9878329B2 (en) 2015-03-23 2018-01-30 SYFR, Inc. Self-contained slide receptacle for patient specimens
CN105214744A (zh) * 2015-10-26 2016-01-06 深圳华迈兴微医疗科技有限公司 一种磁微粒化学发光微流控芯片
EP3162229B1 (de) * 2015-10-28 2022-03-30 Fontem Holdings 1 B.V. Elektronische rauchvorrichtung mit einem flüssigkeitsbehälter mit veränderlichem volumen
ES2828030T3 (es) * 2015-10-30 2021-05-25 Merck Patent Gmbh Dispositivo de preparación de muestras
CN105424449A (zh) * 2015-11-11 2016-03-23 刘洋 一种用于切片染色的导流体结构及切片染色方法
KR102521127B1 (ko) * 2016-02-19 2023-04-13 퍼킨엘머 헬스 사이언시즈, 아이엔씨. 미세유체 혼합 장치 및 방법
CN105891049B (zh) * 2016-04-13 2018-11-23 青岛科技大学 一种研究流体流变行为的方法及狭缝流变仪
SG10202103252VA (en) 2016-09-30 2021-05-28 Tel Array Diagnostics Inc Microfluidic device
CN110573256B (zh) 2016-12-30 2022-09-02 罗氏血液诊断股份有限公司 样品处理系统及方法
WO2018183744A1 (en) 2017-03-29 2018-10-04 The Research Foundation For The State University Of New York Microfluidic device and methods
CN107129930B (zh) * 2017-06-09 2019-11-26 北京百康芯生物科技有限公司 一种全集成核酸检测微流控芯片及其使用方法
CN107606252B (zh) * 2017-08-02 2024-04-30 南京岚煜生物科技有限公司 用于微流控芯片的无源单向阀
CN107557452A (zh) * 2017-08-02 2018-01-09 南京岚煜生物科技有限公司 一种用于核酸扩增检测的微流控芯片
GB2569344A (en) 2017-12-14 2019-06-19 Randox Laboratories Ltd Fluidic card assembly
US10792594B2 (en) * 2017-12-28 2020-10-06 Replegin Corporation Dual pumping arrangement for a hollow fiber filter
DE102018200520A1 (de) 2018-01-15 2019-07-18 Robert Bosch Gmbh Verfahren zum Bereitstellen einer Lösung der Substanz in einer mikrofluidischen Vorrichtung
CN110573882B (zh) * 2018-01-16 2021-06-25 株式会社爱蓓儿 血液凝固时间测量用卡匣以及血液凝固时间测量装置
JP6456530B1 (ja) * 2018-01-16 2019-01-23 株式会社アペレ 血液凝固時間測定用カートリッジ及び血液凝固時間測定装置
EP3749453A4 (de) * 2018-02-07 2021-12-15 The Trustees of the University of Pennsylvania Mikrofluidische vorrichtung mit hohem durchsatz
US10046322B1 (en) 2018-03-22 2018-08-14 Talis Biomedical Corporation Reaction well for assay device
EP3636344A1 (de) * 2018-10-09 2020-04-15 Universiteit Maastricht Probenträgermodul
KR102151648B1 (ko) * 2018-12-03 2020-09-03 광운대학교 산학협력단 미세유체 접속 장치
EP3841386A4 (de) * 2018-12-20 2021-10-20 Leica Biosystems Melbourne Pty Ltd Gleitschalenanordnung
CN109735430B (zh) * 2019-01-28 2021-12-14 武汉纺织大学 一种三维磁泳分离的微流控芯片
CN114340756A (zh) * 2019-08-05 2022-04-12 瑞普利金公司 用于利用交替的切向流的连续处理的装置、系统和方法
US10820847B1 (en) 2019-08-15 2020-11-03 Talis Biomedical Corporation Diagnostic system
CN110554184A (zh) * 2019-09-12 2019-12-10 深圳市科瑞达生物技术有限公司 一种化学发光微流控芯片
CN111214991A (zh) * 2020-01-13 2020-06-02 清华大学 一种高粘度液体常温自动混合装置
CN113275045A (zh) * 2020-02-20 2021-08-20 北京京东方健康科技有限公司 检测芯片及其操作方法、检测系统
CN111551752B (zh) * 2020-04-03 2021-10-08 深圳市科瑞达生物技术有限公司 一种化学发光免疫检测芯片及应用
CN111595836B (zh) * 2020-04-16 2022-09-30 四川轻化工大学 手持式气液相界面化学发光检测笔、装置、系统及其检测方法
CN116348583A (zh) * 2020-05-26 2023-06-27 川赛托斯有限责任公司 用于转染的装置和方法
WO2021259497A1 (en) * 2020-06-26 2021-12-30 Swissmeca Sa Microfluidic chip and pumping device
US20220062898A1 (en) * 2020-08-28 2022-03-03 Leica Microsystems Cms Gmbh Microfluidic Device for Image Multiplexing
GB2599357A (en) * 2020-09-21 2022-04-06 Quantumdx Group Ltd Microfluidic device with positive displacement pump
CN114113567A (zh) * 2020-11-26 2022-03-01 深圳市理邦精密仪器股份有限公司 分子诊断离心测试卡
CN112578111A (zh) * 2020-12-25 2021-03-30 扬州初心科技服务有限公司 一种食品抗生素蠕动多联免疫检测器
JP2024507669A (ja) * 2021-01-21 2024-02-21 ヒューディーエックス インコーポレイテッド マイクロ流体デバイスおよびその高速処理
CN113063780B (zh) * 2021-03-17 2023-11-03 长春长光辰英生物科学仪器有限公司 一种用于光学检测的拭子样品流体系统及其使用方法
GB2611290A (en) * 2021-09-23 2023-04-05 Genome Res Ltd Flow cell interface adaptor
CN115791763B (zh) * 2022-10-20 2023-11-14 胜泰生科(广州)医疗科技有限公司 均相发光检测装置及应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4181650A (en) 1975-08-25 1980-01-01 Maier Charles L Jr Procedure for the assay of pharmacologically immunologically and biochemically active compounds in biological fluids
US4235960A (en) 1977-07-29 1980-11-25 The Medical College Of Wisconsin, Inc. Competitive enzyme-linked immunoassay
NL8000173A (nl) 1980-01-11 1981-08-03 Akzo Nv Toepassing van in water dispergeerbare, hydrofobe kleurstoffen als label in immunochemische testen.
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4810630A (en) 1987-03-30 1989-03-07 E. I. Du Pont De Nemours And Company Use of polyoxyethylene ethers to improve the performance of immunoassays employing peroxidase conjugates
US4849340A (en) 1987-04-03 1989-07-18 Cardiovascular Diagnostics, Inc. Reaction system element and method for performing prothrombin time assay
US5100626A (en) 1990-05-24 1992-03-31 Levin Andrew E Binding assay device with removable cassette and manifold
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
DE4332720C2 (de) 1993-09-25 1997-02-13 Karlsruhe Forschzent Mikromembranpumpe
US6287850B1 (en) 1995-06-07 2001-09-11 Affymetrix, Inc. Bioarray chip reaction apparatus and its manufacture
US5639428A (en) 1994-07-19 1997-06-17 Becton Dickinson And Company Method and apparatus for fully automated nucleic acid amplification, nucleic acid assay and immunoassay
SE504193C2 (sv) 1995-04-21 1996-12-02 Hemocue Ab Kapillär mikrokyvett
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
US7052594B2 (en) 2002-01-31 2006-05-30 Sri International Devices and methods for controlling fluid flow using elastic sheet deflection
US6303389B1 (en) 1997-06-27 2001-10-16 Immunetics Rapid flow-through binding assay apparatus and method therefor
US6037168A (en) 1997-12-31 2000-03-14 Cytonix Corporation Microbiological assembly comprising resealable closure means
SE9800070D0 (sv) 1998-01-14 1998-01-14 Hemocue Ab Blandningsmetod
US6158712A (en) 1998-10-16 2000-12-12 Agilent Technologies, Inc. Multilayer integrated assembly having an integral microminiature valve
ES2316362T3 (es) * 1999-04-20 2009-04-16 Dako Denmark A/S Intercambio de fluidos en una camara sobre un portaobjetos de microscopio.
US6673620B1 (en) 1999-04-20 2004-01-06 Cytologix Corporation Fluid exchange in a chamber on a microscope slide
US6743399B1 (en) 1999-10-08 2004-06-01 Micronics, Inc. Pumpless microfluidics
US6272939B1 (en) 1999-10-15 2001-08-14 Applera Corporation System and method for filling a substrate with a liquid sample
US6569674B1 (en) 1999-12-15 2003-05-27 Amersham Biosciences Ab Method and apparatus for performing biological reactions on a substrate surface
US6309875B1 (en) 2000-02-29 2001-10-30 Agilent Technologies, Inc. Apparatus for biomolecular array hybridization facilitated by agitation during centrifuging
WO2001068238A2 (en) 2000-03-14 2001-09-20 Micronics, Inc. Microfluidic analysis cartridge
CA2402985A1 (en) 2000-03-21 2001-09-27 Brevard S. Garrison Method and apparatus for acoustically controlling liquid solutions in microfluidic devices
US6431212B1 (en) 2000-05-24 2002-08-13 Jon W. Hayenga Valve for use in microfluidic structures
WO2002001081A2 (en) 2000-06-23 2002-01-03 Micronics, Inc. Valve for use in microfluidic structures
ES2232407T3 (es) 2000-12-28 2005-06-01 F. Hoffmann-La Roche Ag Metodo para el procesado de una muestra de acido nucleico mediante la oscilacion de un segmento de una pared de un cartucho, un sistema y un cartucho para realizar dicho metodo.
WO2003015923A1 (en) 2001-08-20 2003-02-27 Biomicro Systems, Inc. Fluid mixing in low aspect ratio chambers
WO2002072264A1 (en) 2001-03-09 2002-09-19 Biomicro Systems, Inc. Method and system for microfluidic interfacing to arrays
US20020159920A1 (en) 2001-04-03 2002-10-31 Weigl Bernhard H. Multiple redundant microfluidic structures cross reference to related applications
DE50212817D1 (de) * 2001-05-25 2008-11-06 Tecan Trading Ag Vorrichtung und Verfahrenseinheit zum Bereitstellen eines Hybridisierraums
US6729352B2 (en) 2001-06-07 2004-05-04 Nanostream, Inc. Microfluidic synthesis devices and methods
US6773677B2 (en) * 2002-01-09 2004-08-10 Caliper Life Sciences, Inc. Slide cassette for fluidic injection
US7223371B2 (en) 2002-03-14 2007-05-29 Micronics, Inc. Microfluidic channel network device
US6843263B2 (en) 2002-06-24 2005-01-18 Industrial Technology Research Institute Partially closed microfluidic system and microfluidic driving method
US7419638B2 (en) 2003-01-14 2008-09-02 Micronics, Inc. Microfluidic devices for fluid manipulation and analysis
US7416892B2 (en) 2003-01-21 2008-08-26 Micronics, Inc. Method and system for microfluidic manipulation, amplification and analysis of fluids, for example, bacteria assays and antiglobulin testing
US6916113B2 (en) 2003-05-16 2005-07-12 Agilent Technologies, Inc. Devices and methods for fluid mixing
DE10336849A1 (de) * 2003-08-11 2005-03-10 Thinxxs Gmbh Flusszelle
DE10352716A1 (de) * 2003-11-05 2005-06-16 Einsle, Xaver Plattform
US7588890B2 (en) * 2004-04-16 2009-09-15 Wei-Sing Chu Device for extracting biological molecules from tissue specimens and methods for preparing the same
EP1614466A3 (de) * 2004-07-08 2006-05-10 Tecan Trading AG System mit Einrichtung zum Verhindern von Luftblasen in einer Hybridisierkammer und entsprechendes Verfahren
US7832429B2 (en) 2004-10-13 2010-11-16 Rheonix, Inc. Microfluidic pump and valve structures and fabrication methods
US20060127886A1 (en) 2004-12-15 2006-06-15 Kaylor Rosann M Sample-efficient lateral flow immunoassay
US7763453B2 (en) 2005-11-30 2010-07-27 Micronics, Inc. Microfluidic mixing and analytic apparatus
AU2007265628B2 (en) * 2006-06-23 2012-12-06 Perkinelmer Health Sciences, Inc. Methods and devices for microfluidic point-of-care immunoassays
US7906317B2 (en) 2007-10-21 2011-03-15 King Car Food Industrial Co., Ltd. Apparatus for thin-layer cell smear preparation and in-situ hybridization
DE502008001596D1 (de) * 2008-06-02 2010-12-02 Boehringer Ingelheim Micropart Mikrofluidische Folienstruktur zum Dosierren von Flüssigkeiten
JP2010078508A (ja) * 2008-09-26 2010-04-08 Toshiba Corp 送液装置
EP2349566B1 (de) 2008-10-03 2016-01-06 Micronics, Inc. Mikrofluidikvorrichtung und verfahren zur durchführung von blutgruppenbestimmung und kreuzprobe
US20110240127A1 (en) 2010-04-02 2011-10-06 Integenx Inc. Fluidic Article Fabricated In One Piece

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11926817B2 (en) 2019-08-09 2024-03-12 Nutcracker Therapeutics, Inc. Microfluidic apparatus and methods of use thereof

Also Published As

Publication number Publication date
CN104136123A (zh) 2014-11-05
EP2802417A2 (de) 2014-11-19
KR102090934B1 (ko) 2020-03-19
KR20140110925A (ko) 2014-09-17
WO2013106458A2 (en) 2013-07-18
JP6190822B2 (ja) 2017-08-30
CN104136123B (zh) 2017-03-01
JP2015510111A (ja) 2015-04-02
WO2013106458A3 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
EP2802417B1 (de) Mikrofluidisches reaktorsystem
US9056291B2 (en) Microfluidic reactor system
EP2041573B1 (de) Verfahren und vorrichtung für mikrofluidische point-of-care-immunoassays
JP2015510111A5 (de)
US11583853B2 (en) Kits and devices for detecting analytes
US20190168221A1 (en) Microfluidic Chips and Cartridges and Systems Utilizing Microfluidic Chips and Cartridges
US7763453B2 (en) Microfluidic mixing and analytic apparatus
US20070042427A1 (en) Microfluidic laminar flow detection strip
US10449538B1 (en) Systems and method for metering and timing of fluid flow in a point-of-care diagnostic cartridge
CN109682962B (zh) 基于微流控芯片的免疫荧光检测系统及检测方法
US20210237050A1 (en) Disposable bioassay cartridge and method of performing multiple assay steps and fluid transfer within the cartridge
US10583435B1 (en) Point-of-care diagnostic cartridge having a lateral flow assaying apparatus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140709

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20171107

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: B01F 11/00 20060101ALI20181130BHEP

Ipc: B01L 3/00 20060101AFI20181130BHEP

INTG Intention to grant announced

Effective date: 20181218

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: GB

Ref legal event code: FG4D

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: PERKINELMER HEALTH SCIENCES, INC.

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013055371

Country of ref document: DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602013055371

Country of ref document: DE

Owner name: PERKINELMER HEALTH SCIENCES, INC., WALTHAM, US

Free format text: FORMER OWNER: MICRONICS, INC., REDMOND, WASH., US

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20190515

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190815

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190915

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190816

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190815

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1132809

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190515

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013055371

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

26N No opposition filed

Effective date: 20200218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200109

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200131

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200131

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190515

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190915

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230526

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231116

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20231121

Year of fee payment: 12